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Abstract 
 
Mutations in methyl-CpG binding protein 2 (MeCP2) have been attributed as the cause of Rett 
syndrome (RTT). RTT is an X-linked neurological disorder affecting approximately 1/10000 
females. MeCP2 is a ubiquitously expressed protein and its main function is to act as a 
transcriptional repressor via association with NCoR/SMRT complex. However, MeCP2 has 
various reported functions and interacting partners. For this reason, the exact role of MeCP2 in 
RTT, its function and acting mechanism are not yet fully known. 
 
In order to address this, the aim of this thesis was to shed light on the protein interactions of 
MeCP2 in a novel way, using proximity labelling (PL). Here, two promiscuous ligases, TurboID 
and miniTurbo, were fused to the C-Terminus of MeCP2 to enable biotinylation of proximal 
proteins. Mouse fibroblast cells were transfected with MeCP2-TurboID and MeCP2-miniTurbo 
and exposed to biotin. The high affinity of biotin to streptavidin allows biotinylated proteins to be 
isolated and identified. 
 
Firstly, I have shown that fusion in the C-Terminus of MeCP2 does not affect its ability to localise 
to the nucleus. Additionally, supplementation with biotin allowed the visualisation of biotinylated 
proteins in mouse fibroblast cells. I have confirmed that protein biotinylation using the named 
ligases can occur in as little as 10 minutes. More exogenous biotinylation occurred in TurboID 
transfected cells than miniTurbo transfected cells. A cell line has been produced of MeCP2- 
TurboID. Overall, PL appears to be a promising avenue of research for identifying protein partners 
of MeCP2. In the future, this will aid more detailed insights into molecular mechanisms of MeCP2 
and, indeed, implications on RTT. 
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1-Introduction 
 
1.1. DNA methylation 
The vertebrate genome is globally methylated (Bird and Taggart.,1980). DNA methylation is a 
common epigenetic mark whereby a methyl group is added to the 5’ position of cytosine residues 
(Fig 1.1). DNA methylation is essential for controlling gene expression amongst various other 
functions (Bird., 2002; Baylin and Ohm., 2006). In mammals, this modification occurs 
predominantly at CpG dinucleotides. Approximately 70% of all CpG dinucleotides are methylated 
in mammals, with the exception of CpG islands (CGIs), CG-rich regions mostly coinciding with the 
promoter of protein-coding genes. CpG islands may become hypermethylated, leading to gene 
silencing. In this context, methyl-CpG binding proteins are vital in the process of DNA methylation-
dependent gene silencing (Ballestar and Wolffe 2001). 
 
DNA methylation has also been found to occur at non-CpG sites, particularly at CpA dinucleotides 
in vitro and the mouse brain (Lister et al.,2013; Guo et al.,2014; Xie et al.,2012), and contributes 
to the neuronal methylome (Kinde et al.,2016). The density of non-CpG methylation increases 
during neuronal maturation, at a time in development when MeCP2 levels are increasing, 
becoming the most predominant form of methylation in adult neurons (Lister et al.,2013; Guo et 
al.,2014; Xie et al.,2012). This indicates a possible role in MeCP2 recruitment to chromatin. 
 
Another DNA modification, 5- hydroxymethylcytosine (5hmC) has gained considerable scientific 
attention. This modification arises from 5 methylcytosine by conversion catalysed by TET (ten 
eleven translocation) proteins (Tahiliani et al.,2009).. This DNA modification has been associated 
with gene enhancers, transcriptional start sites, and gene bodies (Stroud et al.,2011). Its roles in 
gene regulation and DNA methylation are still to be determined. Current suggestions depict that 
5mC to 5hmC may facilitate DNA demethylation via the exclusion DNMT1- a maintenance DNA 
methyltransferase (Tahiliani et al.,2009). 
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Figure 1.1 Chemical structure of cytosine and its modified form. 
 
 
 
1.2. MeCP2 
MeCP2 was characterised by its ability to bind to methylated DNA (Lewis et al.,1992; Meehan et 
al.,1992). In humans, MeCP2, a single gene on the X chromosome at the locus Xq28, codes for 
the 486 amino acid long, chromatin associated MeCP2 protein with established domains. 
Cytosine is frequently methylated and it has been noted that Methyl-CpG often interferes with 
transcription. While MeCP2’s precise molecular function remains unclear, it is known that MeCP2 
binds to methylated cytosine residues (Lewis et al.,1992) and that mutations in this gene underlie 
Rett syndrome (RTT). 
 
MeCP2 is ubiquitously expressed, however, it is expressed at higher levels in the brain. Studies 
have determined the absolute abundance of MeCP2 in unsorted nuclei isolated from mature 
mouse brains as 16x10܃܁⁶ molecules per nucleus compared to 0.5x10⁶܃ molecules per hepatic 
nuclei (Skene et al.,2010). This is comparable to the number of nucleosomes, approximately 
30x10܃܁⁶, suggesting MeCP2’s fundamental role in neurons. 
 
MeCP2 is known to occur in 2 isoforms, or variants, with the main difference between these 
residing in the N-terminus (Kriaucionis and Bird., 2004). One variant, MeCP2_e2, consists of 4 
exons, with the translational domain present in exon 2, gives a protein of 486 amino acids (aa; 
Kriaucionis and Bird., 2004). The second variant, MeCP2_e1 omits exon 2 and gives a protein of 
488 aa. Both isoforms of the protein are expressed in all tissues and function in the same way 
(Kriaucionis and Bird., 2004). Indeed, both protein isoforms are nuclear and colocalise with 
methylated heterochromatic foci in mice (Kriaucionis and Bird., 2004) 
12  
 
MeCP2 is believed to contain two main functional domains: the Methyl-CpG Binding Domain 
(MBD), responsible for binding to methylated DNA (Nan et al.,1993), as well as the NCoR 
interaction domain (NID; Lyst et al.,2013) 
 
1.3 Rett syndrome 
RTT is an X-linked neurological disorder, affecting approximately 1 in 10,000 live females at birth 
(Rett, 1966). Patients are characterised by the presence of a partial or complete loss of acquired 
purposeful hand skills, partial or complete loss of acquired spoken language, gait abnormalities, 
and development of stereotypic hand movements such as hand wringing or washing (Neul et 
al.,2010). Patients develop normally for the first 6-18 months of life, followed by regression in 
purposeful hand use and spoken language, gait abnormalities, and hand stereotypies (Neul et 
al.,2010). RTT is often associated with deceleration in head growth, although this is not required 
for diagnosis. 
 
MeCP2 mutations are well established as being the main cause of RTT (Amir et al.,1999) and 
80% of classic cases are caused by mutations in MeCP2 (Cheadle et al.,2000). Sporadic 
mutations are of MeCP2 are almost exclusively of paternal origin, explaining the high occurrence 
in females (Trappe et al.,2001; Cuddapah et al.,2014; Girard et al.,2001). It had been suspected 
that RTT causing mutations led to embryonic fatality in males, however, males with RTT have 
been reported (Schwartzman et al.,2001; Vorsanova et al.,2001; Neul et al.,2018). Mutations in 
males may arise from maternal inheritance or from mutations occurring in the oocytes (Schanen., 
2001). Overall, there is greater clinical variation in males, complicating diagnosis. Furthermore, 
phenotypes are often more severe in males, leading to recent study including male 
encephalopathy as a diagnostic entity (Neul et al., 2018; Neul et al., 2014). RTT has been 
identified in a comorbid state, affecting boys who, generally, fall into two categories; those with 
47XXY, also known as Klinefelter syndrome, or those with somatic mosaicism (Schwartzman et 
al.,2001). 
 
1.4 Methyl-CpG-Binding Proteins 
In 1984, the first evidence of a protein with specificity for methylated DNA was established (Huang 
et al.,1984). The first protein to be identified by its ability to bind to methylated DNA was named 
methyl-CpG binding protein 1 (MeCP1; Meehan et al.,1989). This was followed by the 
identification of MeCP2 (Lewis et al.,1992; Meehan et al.,1992). 
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The methyl-binding domain (MBD) was characterized by deletion studies of MeCP2 and was 
identified as the minimal domain responsible for interaction with methylated cytosines (Nan et 
al.,1993). The MBD family of proteins takes its definition from the MBD and include MBD1, MBD2, 
MBD3, and MBD4. This group of proteins is so named due to the fact that they contain a methyl- 
CpG-binding domain resembling that of MeCP2 (Hendrich and Bird, 1998). MBD1, MBD2, and 
MBD4, similarly to MeCP2, can bind to DNA containing only one symmetrically methylated CpG 
site and can localise to heterochromatin in transfected cells (Hendrich and Bird., 1998; Fujita et 
al.,1999; Ng et al.,1999). All MBD proteins, apart from MBD4, have been determined to be 
associated with histone deacetylase subunits as part of large complexes. 
 
Mutations in the MBD domain have been associated with MeCP2’s decreased time at 
heterochromatic foci, as assessed by fluorescence recovery after photobleaching (FRAP; Kumar 
et al.,2008, Schmiedeberg et al.,2009). This suggests that binding to DNA is impaired by 
mutations in the MBD in vivo. 
 
1.5 MeCP2 as a transcriptional repressor 
 DNA methylation is typically associated with gene repression (Ballestar et al., 2001). The domain 
responsible for transcriptional repression, the transcriptional repressor domain (TRD) was mapped 
to a specific region of the protein between amino acids 207 and 310 (Nan et al.,1997). It was 
found that native and recombinant MeCP2 repress transcription in vitro from methylated 
promoters but do not repress transcription at unmethylated promoters (Nan et al.,1997). 
Moreover, the proposed mechanism by which MeCP2 acts as a transcriptional repressor was 
based on the fact that biochemical studies showed its interaction with histone deacetylase (HDAC) 
containing complexes Sin3A (Nan et al.,1998). Given the strong correlation between deacetylation 
of histone protein tails and transcriptional repression (Grunstein, 1997), these data suggest that 
MeCP2 represses gene transcription. In line with this finding it was observed that transcriptional 
repression of transporter genes was relieved by treatment with trichostatin A (TSA), a HDAC 
inhibitor (Yoshida et al.,1990). This suggested that this complex promoted deacetylation of 
chromatin, leading to gene repression (Nan et al.,1998). In studies of mice lacking Mecp2 showed 
transcriptional alterations that could not be explained with this simple model of interaction. 
 
Various mechanisms of how MeCP2 leads to transcriptional repression have been proposed. 
These are based on the detection of the binding of MeCP2 to various co-repressor proteins such 
as, nuclear receptor co-repressor (NCoR), and silencing mediator of retinoic acid and thyroid 
hormone receptor (SMRT; Kokura et al.,2001; Stancheva et al.,2003). Indeed, the NCoR/SMRT 
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co-repressor complex was shown to bind between amino acids 269-309- a region known as a 
hotspot for missense mutations, termed the NCoR/SMRT Interaction Domain (NID). Mutations in 
the NID abolished the interactions between MeCP2 and the NCoR-SMRT complex (Lyst et 
al.,2013). It is of note that in this study, the weak Sin3A binding was unaffected by NID mutations 
(Lyst et al , 2013) bringing into question the relevance of this co-repressor interaction in RTT and 
hence highlighting that the model of MeCP2 function is incomplete. 
 
1.6 How MeCP2 mutations cause RTT 
To properly explain RTT pathology, a model of MeCP2 function must explain how the same 
syndrome can arise from null and missense mutations in two main regions of the protein; Methyl- 
CpG Binding Domain (MBD) and the NID (Lyst et al.,2013). One model of MeCP2 function 
suggests that the main function of the protein is to act as a bridge between NCoR-SMRT and 
methylated DNA. Any of the three possible types of mutations (Null, MBD, and NID) would likely 
prevent the recruitment of NCoR-SMRT to chromatin by MeCP2 and hence inhibit transcriptional 
repression. Amongst the most frequent mutations are the following missense mutations; T158M 
and R306C, occurring in the MBD and the NID respectively (Figure 1.2) with T158M being more 
severe (Neul et al.,2008). An alternative model of MeCP2 function proposed that one of the main 
functions of MeCP2 is modulation of chromatin architecture via multiple interactions with DNA. 
The MBD is essential for MeCP2’s ability to bind to 5-methylcytosine and mediates binding to 
methylated CpG dinucleotides found in heterochromatic regions of the chromosome (Lewis et 
al.,1992; Nan et al.,1993). Thus, mutations in the MBD domain impair binding to methylated DNA. 
 
An alternative model of MeCP2 function is that the primary function of MeCP2 in chromatin 
remodelling. The NID has been proposed as having its primary function as a DNA binding domain 
(Heckman et al.,2014). Indeed, the R306C mutation present in this domain is reported to impair 
the interaction between MeCP2 and NCoR/SMRT in the brain  (Lyst et al.,2013). If this model is 
correct, all disease causing mutations affecting the NID would abolish the interaction with 
methylated DNA. 
 
 
 
Figure 1.2. Rett syndrome mutations occur in the Methyl Binding Domain (MBD) and 
NCoR/SMRT Interaction Domain (NID). Schematic of the two main MeCP2 domains, the MBD 
and the NID. 
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1.7 Animal models of RTT 
Animal models have proved invaluable for furthering the understanding of MeCP2 function. An 
early experiment conducted prior to the association of MeCP2 with RTT, aimed to establish the 
role of DNA methylation in mouse development. MeCP2 was mutated in male mice embryonic 
stem (ES) cells using a lacZ reporter gene (Tate et al.,1996). Mutant ES cells lacking MeCP2 
grew as well as parental lines, however, the creation of Mecp2-null mice from these ES cells was 
not possible due to embryonic lethality (Tate et al.,1996). Later, whole brain deletion of MeCP2 
by Nestin-Cre led to a phenotype similar to that of a whole body knock-out (Chen et al.,2001; Guy 
et al.,2001). Mecp2 deletion in post-mitotic neurons in the forebrain, hippocampus, and brainstem, 
but not in the cerebellum or glial cells, led to a delayed and less severe phenotype (Chen et 
al.,2001). This is suggestive of MeCP2’s role in postmitotic, mature neurons rather than in early 
brain development. 
 
Knockin mice recapitulating the T158A mutation exhibited various RTT like symptoms including 
developmental regression, motor dysfunction and learning deficits (Goffin et al., 2011). 
Interestingly, mice with MeCP2 duplication syndrome, overexpressing MeCP2, show similar RTT 
like symptoms as in models lacking MeCP2 (Na et al., 2012). Similarly, studies on mouse brains 
have revealed that protein depletion and gain of function both compromise cell morphology, 
neurotransmission, and processes supporting memory and learning (Na et al.,2013). These data 
suggest that both loss and gain of MeCP2 function result in the exhibition of similar symptoms 
and, thus, that the level of MeCP2 must be carefully regulated. 
 
Considering that RTT is a neurological disorder and MeCP2’s high abundance in the brain, it is 
important to acknowledge MeCP2 in a neural context. In a study that purified the MeCP2 from the 
brains of Mecp2-EGFP knockin mice, MeCP2 was found to interact with transducin-beta like factor 
1 (TBL1; Lyst et al.,2013). A peptide comprising of MeCP2 residues bound directly to N-terminal 
regions of NCoR1 and SMRT and their shared homodimeric subunits of TBL1 and TBLR1 (Fig 
1.3;Lyst et al.,2013), supporting the presence of MeCP2 binding sites on NCoR/SMRT 
complexes. Studies have shown that polymorphisms elsewhere in the protein are found in the 
general population, suggesting that other protein regions may be dispensable. Conversely, 
MeCP2 is almost abundant enough in the genome to coat the chromosome (Skene et al.,2010) 
hence the amount of MeCP2 supersedes the number of NCoR repressors, contradicting its 
proposed function. 
 
Importantly, activation of a silenced Mecp2 allele after phenotype presentations reverses these 
RTT-like symptoms (Guy et al., 2007; Robinson Ebert et al., 2013). This has raised the hope 
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that RTT is a curable disorder. But, we still have little understanding of the mechanisms by 
which loss of. Overall, these data suggest that RTT phenotypes can be rescued, at least in 
mice, highlighting the possibility for treatment and hence the need for further understanding of 
the etiology of RTT. 
 
 
 
 
Figure1.3 The NCoR complex interacts with MeCP2 via a TBLR1 subunit. Illustrative 
schematic of depicting MeCP2 bound to heterochromatin and associated with NCoR/SMRT via 
TBLR1. This association leads to transcriptional repression (Lyst et al.,2013). Created with 
biorender. 
 
1.8. MeCP2 as a transcriptional activator 
 
MeCP2 has long been considered a transcriptional repressor (Nan et al., 1997), however, recently 
its ability to act as both a transcriptional activator and repressor has been suggested. Initially, 
global expression profiling, using microarrays to measure gene activity throughout the genome, 
did not reveal significant differences in gene expression patterns in the brains of MeCP2- null 
mice compare to wild-types (Tudor et al.,2002). Subsequent analyses of specific brain regions, 
such as the hypothalamus, in MeCP2-null mice and mice overexpressing MeCP2 showed that 
numerous genes are consistently and reciprocally dysregulated, although subtly (Ben-Shachar et 
al.,2009; Chahrour et al.,2008). It was shown that more genes were downregulated than 
upregulated in the hypothalamus of MeCP2 knock-out mice. The study showed that the majority 
of downregulated genes in MeCP2- null mice showed changes in patterns of expression and were 
rather upregulated and vice versa (Chahrour et al.,2008). 
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The mechanism proposed for MeCP2’s role in transcriptional activation is based on MeCP2’s 
recruitment of cyclic-AMP responsive element binding protein 1 (CREB1; Figure 1.4) to target 
gene promoters to activate transcription (Chahrour et al.,2008). However, the evidence for this is 
not compelling as experiments have not been replicated by others. 
 
 
 
 
Figure 1.4. MeCP2 can function as a transcriptional activator when bound to CREB. 
Binding to CREB activates transcription. Adapted from Chahrour et al.,2008. Created with 
Biorender. 
 
 
 
1.9. Other functions of MeCP2 
 
1.9.1. MeCP2 in chromatin remodelling 
 
Apart from the protein’s well established role as a transcriptional repressor, MeCP2 has reported 
involvement in various other mechanisms. MeCP2 has been reported to be involved in controlling 
chromatin structure (Zlatanova ., 2005; Chadwick and Wade., 2007). MeCP2 is able to modulate 
chromatin architecture in a number of ways; by condensing DNA through regulating long range 
interactions (Horike et al.,2005), the formation of higher order chromatin structures (Georgel et 
al.,2003; Agarwal et al.,2011), and the formation of chromatin loops and DNA bridges (Georgel et 
al.,2003; Nikitina et al.,2007). MeCP2’s chromatin associated role is evidenced through its 
localisation to DAPI stained heterochromatin regions of the nuclei (Zachariah et al.,2012; Craig et 
al.,2003). 
1.9.2 Regulation of chromatin structure by replacement of histone H1 
 
MeCP2’s function in regulating chromatin structure may occur through displacement of histone 
H1. Experiments involving in vitro assembled protein highlighted that MeCP2 was able to compete 
with histone H1 (Nan et al., 1997). Furthermore, it has been observed that these proteins seem 
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to compete for the same substrates in vivo as microinjection of either MeCP2 or Histone H1 
increased the FRAP kinetics of the other (Ghosh et al.,2010). There is evidence that this could be 
relevant in the brain; neurons from Mecp2-null mice have been found to express higher levels of 
H1 (Skene et al.,2010). Together, these data could present a mechanism by which MeCP2 
regulates chromatin architecture. 
 
1.9.3 MeCP2 in RNA splicing 
 
It has been proposed that MeCP2 plays a role in RNA splicing. The main mechanism by which 
this  occurs is by MeCP2 directly interacting with Y- box binding protein 1 (YB-1), a Y box 
transcription factor able to regulate alternative splicing. Additionally, expression of MeCP2 by 
transient transfection promotes the inclusion of variable exons in a reporter minigene. It has also 
been observed that depletion of MeCP2 in human cell lines leads to abnormal alternate splicing 
events. While MeCP2 has been identified as a methylation dependent transcriptional repressor, 
RNA profiling from mice lacking the protein did not reveal significant changes in gene expression 
(Young et al.,2005). Changes in the alternative splicing of genes, including DLX5, Fgf2-5, Fut8, 
and Nf1 have been observed in mouse models of RTT (Mecp2308/Y) (Young et al.,2005). The 
latter, alongside reports of MeCP2 binding with RNA binding protein YB-1 (Young et al.,2005) 
support MeCP2’s role in RNA splicing. 
 
1.9.4 MeCP2 in microRNA regulation 
MicroRNAs are non-coding RNAs that play key roles in gene expression regulation (Lee et 
al.,1993). These are short (22 nucleotides long), single stranded RNA molecules (Lee et al.,1993). 
 
MicroRNAs are involved in gene silencing. One study recently described role of MeCP2 in the 
regulation of MicroRNA (miRNA) expression in the prenatal brain. miR-132 and miR-212 have 
been reported to bind to 3’ UTR of MeCP2 and post transcriptionally diminish translation (Wada 
et al.,2010). MeCP2 regulates miRNA processing is by interacting with DGCR8 in order to halt 
the formation of Drosha-DGCR8 complex thus leading to a halt in transcription and translation 
(Cheng et al.,2014). Despite this, retesting of the role of MeCP2 in microRNA regulation has not 
led to a consensus. 
 
1.9.5 Silencing of retrotransposition 
 
The mammalian genome is made up of more than 35% repetitive sequences (Yoder et al.,1997). 
Repetitive sequences, such as retrotransposons, have been found to be highly methylated in the 
mouse brain and, interestingly, MeCP2 associates with these regions, as highlighted by chromatin 
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immunoprecipitation (Muotri et al.,2010). Additionally, these elements are more abundant in the 
nuclei of Mecp2-null, suggesting that MeCP2 may act to reduce their expression (Skene et 
al.,2010). Considering this, increased transposition may be characteristic of MeCP2 deficiency. 
On par with the latter, increased L1 retrotransposition has been found in the brains of RTT patients 
as well as in Mecp2-null mice, compared to WT controls (Muotri et al.,2010). It has been proposed 
that the main function of DNA methylation is to protect the genome from retrotransposition events 
by transcriptional repression of these transposable elements (Yoder et al.,1997). These data thus 
reinforce MeCP2’s role as a transcriptional repressor, however, further research into the protein’s 
function is required to resolve controversies regarding its role as a transcriptional activator and 
repressor. 
 
 
1.10. A single function for MeCP2? 
Despite this evidence that MeCP2 acts as a multi-functional hub, a recent study suggests that 
MeCP2 has a single dominant function: to physically connect DNA with the NCoR/SMRT complex 
(Tillotson et al., 2017). In this study, the authors generated an MeCP2 construct whereby they 
removed almost all amino-acid sequences except the MBD and NCoR/SMRT interaction domain. 
They found that mice expressing this minimal protein survive for over one year with only mild 
symptoms. Moreover, they found that this minimal protein was able to prevent or reverse 
neurological symptoms when introduced into MeCP2-deficient mice by genetic activation or virus- 
mediated delivery to the brain. In contrast, mice lacking both the N- and C-terminal regions 
(approximately half of the native protein) are phenotypically near-normal. Together, these results 
suggest that the predominant function of MeCP2 is to bind methylated DNA and interact with the 
NCoR/SMRT complex. These results are supported by the finding that missense mutations that 
cause Rett syndrome are concentrated in two discrete clusters that coincide with the MBD and 
NCoR/SMRT interaction domain (Lyst et al., 2013). 
 
 
 
1.11. MeCP2 interactions with importins 
 
1.11.1 Nuclear Localisation Signal 
 
MeCP2 is ubiquitously expressed throughout the genome and is present in the cell nuclei. The 
nucleus is separated from the cytoplasm by a nuclear membrane, which has an embedded 
nuclear pore complex (NPC). Small proteins are able to diffuse to the nucleus passively through 
the NPC, however, larger proteins are unable to do this. Larger proteins require a nuclear 
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localisation signal (NLS) in order to enter the nucleus. The NLS is a short motif that binds to 
proteins and mediates active transport through the NPC (Sorokin et al.,2007). 
 
MeCP2’s NLS was initially established by expression of protein fragments as beta-galactosidase 
fusion proteins and assaying their localization in mouse fibroblasts (Nan et al.,1996). The latter 
system required the NLS for the MeCP2’s localisation to the nucleus. This is contradictory to the 
finding that the NLS is dispensable for MeCP2 localisation (Lyst et al.,2018). A likely explanation 
for the above is that beta galactosidase bound to MeCP2 may obligatory require active transport 
through the NPC. This hypothesis is hence suggestive of smaller MeCP2-EGFP fusions being 
able to enter the nucleus and be retained there by its affinity to DNA (Lyst et al.,2018) and that 
the only requirement for this to happen is the presence of an intact MBD. 
 
Considering that the NLS appears not to be required for localisation of MeCP2 to the nucleus, a 
question is raised regarding the purpose of its interaction with KPNA3 and KPNA4. Disease 
progression in a mouse model of RTT was not impacted by a mutation abolishing the binding of 
MeCP2 NLS to importins KPNA3 and KPNA4 (Lyst et al.,2018). One possibility for the function of 
MeCP2’s interaction with importins could be related to their proposed function as chaperones 
(Lyst et al.,2018). 
 
While the general consensus remains that MeCP2 does not require KPNA3 and KPNA4 to localise 
to the nucleus, there is recent evidence implicating importin alpha 5 in MeCP2’s nuclear 
localisation. Five importin alpha knockout mouse lines were produced (Panayotis et al.,2018). 
This study found that a knockout of importin alpha 5, but not importin alpha 3 and importin alpha 
4, reduced MeCP2 nuclear localisation, particularly in hippocampal neurons (Panayotis et 
al.,2018). These data suggest it’s premature to assume MeCP2’s complete independence of this 
importin for localisation. Reinforcing the above, hippocampal neurons lacking importin alpha 5 
revealed changes in presynaptic plasticity and modified expression of MeCP2 regulated genes 
(Panayotis et al.,2018). 
 
1.12 TBLR1 
The TBLR1 gene is located in 3q26.32 and is approximately 178bps long (Zhang et al.,2006). 
Human TBLR1 exists as two isoforms, differing at their carboxyl end (Zhang et al.,2006). The 
NCoR-SMRT complex, as isolated by immunoaffinity chromatography was shown to bind directly 
to TBLR1, via SMRT, which in turn binds directly to HDAC3. This suggests that TBLR1 has a role 
in the regulation of NCoR-SMRT. 
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1.12.1 TBLR1 and its importance in RTT aetiology 
 
As mentioned previously, RTT mutations outside of the MBD are clustered in the NID (Lyst et 
al.,2013). A mutation in this domain, R306C, causes a severe RTT like phenotype in mice (Lyst 
et al.,2013). Additionally, models of MeCP2 duplication syndrome suggest that the MBD and NID 
must be intact for an adverse molecular pathology to develop (Lyst et al.,2013). The above facts 
suggest that the NID mediates critical functions of MeCP2. This could be through disruption of the 
recruitment of NCoR/SMRT corepressor complexes to chromatin. Alternatively, a major function of 
the NID could be to perform DNA binding. Previous data suggests that co-repressor recruitment 
to DNA is a core MeCP2 function that is disturbed in RTT (Lyst et al., 2013). It is hypothesised 
that this could be due to the loss of the DNA-MeCP2-NCoR/SMRT bridge compromising brain 
function by preventing transcriptional repression (Lyst et al., 2013). 
 
When investigating the molecular basis of MeCP2-NCoR/SMRT interaction, previous studies 
have found that the TBL1 and TBLR1 subunits are direct MeCP2 binding partners. Furthermore, 
a crystal structure of the MeCP2-TBLR1 complex revealed that the four MeCP2 NID residues 
directly contacting TBLR1 are the same as those mutated in RTT (Kruusvee et al.,2017). The 
above suggests that one of the main functions of the NID could lie in the maintenance of this 
interaction. Furthermore, a study has shown that the NCoR subunit TBLR1 binds directly to 
MeCP2 via the C-terminus WD40 domain (Kruusvee et al.,2017). Reinforcing the main function 
of the NID as maintenance of MeCP2’s interaction with TBLR1 is the fact that mutations in the 
TBLR1 WD40 domain were also found to prevent recruitment to the heterochromatic foci in vitro. 
The most common RTT-causing missense mutation in the NID is R306C, responsible for 5% of 
all cases. Mouse models of this mutation display the same phenotypic characteristics as other 
RTT mouse models, confirming pathogenicity (Guy et al.,2001; Brown et al.,2016; Lyst et 
al.,2013). Studies on transcriptional analyses have displayed the same patterns of dysregulation 
in R306C knock-in mice as the other models (Gabel et al.,2015). Overall, this data is evidence 
that disruption of the interaction between MeCP2 and the NCoR complex suffices in causing both 
the neurological defects and transcriptional changes characteristic of all RTT models 
 
As mentioned previously, MeCP2 has been found to be nearly as abundant in the brain as the 
histone octamer (Skene et al.,2010). However, MeCP2 binds preferentially to methylated DNA 
(Skene et al.,2010). Additionally, it has been established that DNA methylation favours 2 MeCP2 
molecules per nucleosome (Nikita et al.,2007; Skene et al.,2010) but there is enough MeCP2 in 
the brain to completely coat the entire nucleosome. Considering the above findings with regards 
to NCoR complex interaction with MeCP2 via a TBLR1 subunit, it may then be hypothesised that 
the excess presence of MeCP2, compared to nucleosomes, elucidates a specific function to bind 
to TBLR1. 
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1.13 Using biotinylation for identification of protein interaction 
networks 
Despite decades of research and a well-documented interaction with NCoR, the interactome of 
MeCP2 is not yet established. Previous proteomic analysis methods, such as co- 
immunoprecipitation, have various technical limitations. Such techniques have the possibility of 
producing artefacts due to frail purification and contamination (Miernyk and Thelen., 2008). Also, 
co-immunoprecipitation also fails to identify weak or transient interactions. Currently used 
methods for the identification of protein-protein interactions involve using yeast 2 hybrids and 
affinity complex purification. 
 
Biotin tagging of proteins is a useful tool for studying protein interactions. Biotin is a small, organic 
molecule with binds to avidin and streptavidin with high affinity (Weber et al.,1989). Biotinylation 
may be achieved by chemical or enzymatic means. Chemically, biotinylation occurs via the 
modification of protein amino groups with biotin-N-hydroxysuccinimide (Weber at al., 1989) 
Enzymatic biotinylation, however, is limited to proteins naturally containing this modification. Such 
proteins are mostly biotin-dependent carboxylases and decarboxylases (Chapman-Smith and 
Cronan., 1999). Biotinylation is one of the most commonly used protein labelling methods for 
facilitation of detection, immobilisation, and purification (Bayer and Wilchek., 1990). 
 
Biotin protein ligases (BPLs) used to catalyse protein biotinylation are highly specific to their 
protein substrates and, thus, are not general protein modification enzymes (Choi-Rhee et 
al.,2004). BirA, E.coli’s BPL, is an enzyme with the ability to catalyse covalent attachment of biotin 
to the lysine side chain within a 15 amino acid (aa) peptide termed the avi-tag (Barker and 
Campbell.,1981; Schatz 1993; Beckett et al.,1999; Cull and Schatz.,2000) E. coli B strain AVB101 
contains an engineered pACYC184 plasmid with an inducible BirA gene. It is designed for co- 
expression of BirA and avi-tagged protein of interest for in vivo biotinylation. The 15 aa peptide 
has been widely used as a tag for protein biotinylation and purification. There are few other 
conjugation pairs that have the same high affinity and utility, and hence there are limitations on 
the development of applications that require more than one conjugation handle. By expanding the 
specificity of biotin ligase, it may prove possible to generate a wider array of peptide- and protein- 
labelling reagents (Lu et al.,2014). 
 
Enzymatic biotinylation appears to be an ideal tag, however, the avi tag does not occur naturally 
and frequently in mammalian proteins. It was important to address this as biotinylated protein 
species are rare, meaning that endogenous biotinylation is reduced (Cronan., 2005). Additionally, 
the specificity and strong binding of biotin to streptavidin and avidin allow the sensitive detection 
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of biotinylated proteins (Cronan., 2005). To be able to use the above benefits of biotinylation, a 
mutant form of BirA was engineered to contain a R118G mutation. BirA-R118G, known as BirA*, 
showed a higher level of promiscuous biotinylation (Choi-Rhee et al.,2004). This method allows 
for identification of weak or transient protein interactions. 
 
This approach for identification of neighbouring and interacting proteins is based on the use of a 
promiscuous prokaryotic biotin protein ligase. Based on BirA*, a biotin ligase was fused to a 
protein of interest, and then introduced into mammalian cells where it biotinylates vicinal proteins. 
Biotinylated proteins were then isolated and identified by methods such as mass spectrometry. 
This strategy, called BioID, was used to identify candidate proteins that are proximate to and/or 
interact with human lamin A (LaA), a well characterized component of the nuclear envelope (NE 
Roux et al.,2012). Aside from its use in mammalian cells, BioID has also been used for 
identification of interacting partners of the Asc1 proteins in yeast (Opitz et al.,2017), and for 
Identification of complexes mediating postsynaptic inhibition in mice neuronal cells (Uezu et 
al.,2016). Overall, data suggest that PL has widespread applications for shedding light on protein- 
protein interactions. 
 
There are numerous limitations in the traditional methods used to study protein interactions, 
including limitations to isolation in vitro. Immunoprecipitation, one of the most commonly used 
techniques for studying protein-protein interactions, enriches proteins on the biochemical basis of 
their affinity to the bait protein (Branon et al.,2018). Proximity biotinylation, on the other hand, is 
based on through space biotinylation of proteins 1-10 nm from the bait (Figure 3A; Branon et 
al.,2017). 
 
Despite extensive research, there is still a lack of understanding regarding MeCP2 target genes 
(Horvath and Monteggia., 2017). A main reason for this is the fact that MeCP2 is an X linked 
gene, hence, a form of heterogeneity is added owing to X chromosome inactivation (Horvath and 
Monteggia., 2017). As a means of addressing the above, an in vivo, cell specific biotinylation 
system, combined with fluorescent activated cells to examine the effects of MeCP2 causing 
mutations on transcription was designed (Johnson et al.,2017). 
 
 
1.13.1 Engineering MeCP2 to identify its targets 
 
Biotin tagging has been recently used to reveal insights into the RTT transcriptome. Homologous 
recombination of MeCP2 to insert an affinity tag upstream of the protein’s stop codon (Johnson et 
al.,2017) has been achieved. This tag comprised of a TEV protease cleavage site and a 15aa- 
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avi motif (Johnson et al.,2017). This motif can be post-translationally labelled with BirA (Johnson 
et al.,2017). The above approach was combined with an allelic series of Knock-in mice carrying 
frequent RTT mutations (Johnson et al.,2017). The above enabled the selective profiling of RTT 
associated nuclear transcriptomes (Johnson et al.,2017). Recently, more efficient mutant 
enzymes have been engineered, enabling the exploration of new avenues of identifying protein 
interactions. 
 
1.14 Proximity labelling using TurboID and miniTurbo 
 
The enzymes most commonly used for PL are; APEX2, and BioID (Roux et al.,2012; Branon et 
al.,2018). One of the major advantages of APEX labelling is its speed, enabling tagging of proteins 
in 1 min or less, and its versatility. On the other hand, APEX labelling requires H₂O₂, toxic to living 
samples (Branon et al.,2018). Contrastingly, BioID labelling is non-toxic and only requires the 
addition of biotin for the initiation of tagging. A major disadvantage of BioID is its slow kinetics 
requiring very long labelling times of approximately 18-24 hours (Branon et al.,2018). To address 
this, yeast display based directed evolution was used to engineer two BirA mutants (Figure 1.5; 
Branon et al.,2018). 
 
Two promiscuous ligases, TurboID (35kD) and miniTurbo (28kD) were yielded. TurboID was 
yielded with 15 mutations relative to wild-type (WT) BirA, and miniTurbo with its N-terminal domain 
deleted and 13 mutations relative to WT BirA (Branon et al., 2018). These mutants were up to 26-
fold more active than BioID, enabling labelling in as little as 10 minutes (Branon et al.,2018). 
Additionally, TurboID can produce more biotinylated material in 1 hour than BioID produces in 18 
hours (Branon et al., 2018). These data suggest TurboID and miniTurbo enable proximity labelling 
(PL) to be performed efficiently, in new settings and thus broaden the scope for new discoveries. 
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Figure 1.5. Previously used BioID is replaced in proximity labelling by TurboID and 
miniTurboID. a) Schematic of how BioID is used for proximity labelling (PL). b) Schematic of 
ligase structure of TurboID (left) and miniTurbo (right) highlighting differences resulting from 
mutations. N-Terminal domain is absent in miniTurbo. Other mutated sites mutated are shown in 
red and include the absence of S263P and M241T (Taken from Branon et al., 2018). 
 
Two enzymes instead of one were engineered due to their unique properties. TurboID is more 
active and hence is most suitable for when biotinylation maximisation is the priority (Branon et 
al.,2017). It is of note that small amounts of promiscuous biotinylation have been witnessed to 
occur prior to the addition of biotin. This suggests that TurboID is able to utilise the small amounts 
of biotin in cells and organisms grown in media for example (Branon et al., 2017). Nearly all 
eukaryotes import biotin, as they cannot biosynthesize their own. Interestingly, bacteria, which 
can make their own biotin, did not give TurboID background prior to exogenous biotin addition. 
Overall, the use of TurboID and miniTurbo catalysed proximity labelling allows further 
understanding of the interacting partners of MeCP2 while overcoming the issues of toxicity and 
kinetics. 
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1.15 Hypotheses 
 
We hypothesise that fusing a promiscuous biotin ligase to MeCP2 will allow for the efficient and 
unbiased labelling of MeCP2 interacting proteins (Figure 1.5). 
 
 
 
 
Figure 1. 6 Elucidating interacting proteins of MeCP2 using proximity labelling. Schematic 
showing our hypothesis for this project. (A) MeCP2 is known to interact with the NCoR/SMRT 
complex. (B) Fusion of the promiscuous biotin ligase, TurboID, to MeCP2 and addition of 
exogenous biotin causes the biotin ligase to biotinylate proximal proteins that interact with MeCP2. 
Biotinylated proteins can then be recognised by streptavidin. Streptavidin-coated beads can purify 
the biotinylated proteins from cell lysates for further analysis. miniTurbo acts in the same way. 
 
1.16 Aims 
Despite nearly three decades of research on MeCP2, its molecular function and the role it plays 
in RTT is still not fully elucidated. In addition to the above, the previous studies have attempted to 
shed light on the protein interactions of MeCP2 have done so using immunoprecipitation. In this 
project, I propose to generate recombinant constructs consisting of TurboID and miniTurbo and 
evaluate whether these biotinylate proteins in NIH-3T3 fibroblast cells. Overall, this study hoped 
to use novel PL to confirm and identify novel protein interactions of MeCP2. 
The aims of this thesis were: 
1: To search for novel proteins (using TurboID and miniTurbo) and confirm existing interactions 
with MeCP2 
2: To compare biotinylating efficiency of conjugated TurboID and MiniTurbo. 
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3: To clone TBL1 into TurboID. 
 
 
2- Materials and Methods 
 
2.1 Generating recombinant plasmid constructs 
 
Sequence analysis revealed that cutting out EGFP would conserve the N terminus of MeCP2 and 
allow enough space for fusion of TurboID and miniTurbo. The restriction enzymes used were 
NOTI (NEB) and BamHI-HF (NEB). The next step was to amplify the insert DNA. As the insert 
DNA, did not have restriction sites in the correct orientation, I designed primers with the restriction 
site sequences included (Table1). 
 
Table 1- Primers used for PCR and their sequence. 
 
Primer Sequence 
TurboID (FWD) 5’-TAA GGA TCC G ATG TAC CCG TAT GAT GTT CCG-3’ 
 
TurboID (RVS) 
 
5’-TTA GCG GCC GCT CAC ACC TTC CTC TTC TTC TTG-3’ 
*Primers for TurboID and miniTurbo were the same 
 
2.2 Cloning of TurboID and miniTurbo plasmids 
 
Sequence analysis enabled identification of antibiotic resistance genes of MeCP2-EGFP, TurboID 
and miniTurbo. It was revealed that MeCP2-EGFP displayed resistance to Kanamycin While 
TurboID and miniTurbo held resistance to ampicillin. 
 
Agar (Miller) plates were prepared by adding 20 g of Agar to 500 ml of deionised water followed 
by autoclaving. The appropriate antibiotics were added to the molten Agar to a final concentration 
of 30 µg/ml and the agar was poured onto plates. A sterile pipette tip was used to make contact 
with the plasmid stab cultures and used to streak the plates containing appropriate antibiotic. 
Plates were incubated at 37 ℃ for 12-18 hours. 
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2.2.1 DNA extraction from bacterial colonies 
 
2.2.2 Overnight culture 
 
A sterile pipette was used to extract a single colony from the plates. The tip was ejected onto a 
15 ml tube containing LB broth (10 g LB miller in 500 ml deionised water) and 5 µl of the 
appropriate antibiotic. Tubes were incubated in a shaking incubator for at least 12 hours at 225 
rpm at 37 ℃. 
 
2.2.3 Glycerol stocks 
 
Glycerol stocks of every plasmid and construct were made using overnight bacterial growth. 
Briefly, 500 µl of overnight growth were added to 500 µl 50% glycerol in 2 ml screw top tubes. 
Stocks were kept at -80 ℃. 
 
2.2.4 Miniprep DNA extraction 
 
DNA extraction occurred according to manufacturer’s (Qiagen) guidelines. Briefly, 4 ml of 
overnight culture underwent centrifugation at approximately 6,000 x g for 5 minutes at room 
temperature. The pellets were resuspended in 250 µl buffer P1 followed by addition of Buffer P2. 
Incubation occurred for 5 minutes prior to the addition of 350 µl of Buffer N3. Tubes were 
centrifuged for 10 minutes and the supernatant added to the spin column, followed by 60 seconds 
centrifugation. The spin column was then washed with 0.5 ml Buffer PB followed by centrifugation. 
The spin column was then washed with 0.75 ml buffer PE followed by centrifugation (60 s). This 
was followed by centrifugation (60 s) to remove residual wash buffer. DNA was eluted onto a 
clean microcentrifuge tube by adding 30 µl buffer EB to the spin column followed by centrifugation 
(1 min). 
 
2.2.5 Midiprep DNA extraction 
 
DNA to be used for transfections was extracted using a Midiprep Kit (Qiagen). Briefly, overnight 
culture (30 ml) was centrifuged at 6,000 x g for 15 minutes at 4 ℃. The pellet was resuspended 
in buffer P1 followed by lysis in buffer P2 While being incubated at room temp for no longer than 
5 minutes. Lysis was followed by neutralisation with 4 ml buffer P3 and incubation on ice for 15 
minutes. Neutralisation was followed by centrifugation at 20,000 xg for 30 min (4 ℃) and re- 
centrifugation for 15 min under the same conditions. Buffer QBT (4 ml) was used to equilibrate a 
column and supernatant added to the column. Column was then washed with 2 x 10 ml QC and 
DNA eluted with 5 ml Buffer QF. 
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2.2.6 PCR of insert DNA fragment 
 
After I designed primers with restriction sites in the correct orientation (Table 1), a PCR was 
conducted (Figure 2.1). Each reaction was made to 20 µl and set up as follows; 4 µl 5X Reaction 
buffer, 1 µl FWD primer (10 µM), 1 µl (10 µM) RVS primer, template DNA (0.3 ng), 0.4 µl dNTPS 
(10 mM), 0.2 µl Q5 Taq polymerase (NEB). Reactions were performed according to the following 
programme; initial denaturation at 98 ℃ for 2 min followed by 32 cycles of 98 ℃ for 10 s, extension 
at 70 ℃ for 30 s followed by 70 ℃ for 45 s, and annealing at 72 ℃ for 2 min. 
 
2.2.7 PCR DNA Purification and restriction digest 
 
Following PCR, PCR products were purified according to manufacturer’s (Qiagen) guidelines. 
Briefly, Buffer PB (5 volumes) were added to PCR reaction (1 vol), the mix was then added to the 
spin column and centrifuged for 60 s. Then, Buffer PE (0.75 ml) was added to the spin column 
and centrifugation occurred for 60 s. DNA was eluted with 30 µl Buffer EB. 
 
A restriction digest of the purified PCR product (insert) as well as the vector was performed as a 
standard 20μL double digest with reagents: BamH1-HF(NEB) 0.4μL, Not1-HF (NEB) 0.4 μL, 10X 
CutSmart Buffer 2 μL (1X), DNA 0.3 μg, ddH20 to 20 μL. This was carried out for at least 30 minutes. 
Digested DNA fragments were separated on a 1% TAE gel. 
 
2.2.8 Gel extraction, DNA ligation and plasmid amplification 
 
Post gel electrophoresis, the bands of interest were gel extracted according to manufacturer’s 
(Qiagen) guidelines. Briefly, the bands of interest were excised, and Buffer QG (3 vols) were 
added to the gel fragment and the mix was incubated at 50 ºc. Isopropanol was added to the mix 
and this was applied to a spin column followed by centrifugation. Buffer PE (0.75 ml) was used to 
wash the DNA and Buffer EB was used to elute the DNA. 
 
The concentration of purified DNA was measured using a nanodrop spectrophotometer and the 
vector (50 ng) was ligated with the insert DNA (30 ng) using T4 DNA ligase (NEB; Fig 2.1) and 
incubated at 16ºC overnight according to the manufacturer’s protocol. Heat inaction of the ligation 
products occurred at 65 ºC for 10 minutes and the ligation product was used for transformation of 
DH5-α E.Coli competent cells. The cell and ligation product mix was heat shocked at 42 ºC for 45 
seconds and incubated at 37 ºC for 1 hour at 225 rpm. Transformations were spread onto 30 
µg/ml Kanamycin plates. The DNA from the resulting colonies was extracted by miniprep (Qiagen) 
according to manufacturer’s guidelines and verified 
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by restriction digestion using NotI and BamHI enzymes followed by electrophoresis, to check for 
the presence of both plasmids (Fig 3.1). This was followed by sequencing. 
 
 
 
 
A) 
 
PCR amplification Ligation 
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PCR amplification Ligation 
 
 
 
 
 
 
Figure 2.1 Schematic of cloning procedure of TurboID and miniTurbo into 
MeCP2.Compared to MeCP2, a) TurboID and b) miniTurbo had NotI and BamHI restriction sites 
in the wrong orientation. Primers were designed with restriction sites sequences for BamHI and 
NotI and PCR of the insert plasmids was conducted using these leading to the insertion of 
restriction sites in the correct orientation via ligation and transformation of competent cells. The 
transformation product was spread on Kanamycin plates and only plasmid containing bacteria 
would hence be able to grow. 
 
2.3 Mammalian cell culture 
NIH-3T3 cells were cultures as a monolayer in DMEM growth media (supplemented with 10% v/v 
foetal bovine serum (FBS; Gibco), 25 mM glucose, 1 mM sodium pyruvate, 50 units/mL penicillin, 
and 50 μg/mL streptomycin) at 37°C under 5% CO2. 1% penicillin-streptomycin (Gibco). Cells 
were cultured in 75 cm2 flasks (corning) in 15 ml of complete medium. When cells reached 
approximately 90% confluence, they were washed with PBS, trypsinised with 2 ml trypsin for 
approximately 5 minutes and seeded in a 1:10 dilution. 
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For imaging experiments, cells were counted in a haemocytometer and seeded at the desired 
density. For this purpose, cells were grown in 24 well plates with 500 µl growth medium. For 
western blotting, cells were grown on polystyrene 6-well plates with 2.5 mL growth medium. 
 
 
2.4 Calcium phosphate transfection of NIH-3T3 Cells with MeCP2-TurboID 
and MeCP2-miniTurbo 
NIH-3T3 cells (1x104) were calcium phosphate transfected in order to establish protein 
functionality and localisation in cells. Two tubes were prepared for each construct (MeCP2-EGFP, 
MeCP2-TurboID and MeCP2-miniTurbo); one containing CaCl2 (2.5 M) and the other containing 
HEPES Buffered Saline (HBS). The appropriate DNA construct (1 µg) was diluted in CaCl2..The 
HBS was added to the DNA-CaCl2 solutions in a dropwise manner followed by 30 minutes 
incubation in the dark. This solution forms a calcium phosphate precipitate that is directly layered 
onto cells. The solution was then used for transfection and 20 µl of the DNA-CaCl2 were added to 
the wells in a dropwise manner. This is followed by overnight incubation at 37 °C. 
 
 
 
2.5 Immunocytochemistry of MeCP2-EGFP, MeCP2-TurboID, and MeCP2- 
miniTurbo 
For fluorescent imaging experiments, NIH-3T3 cells were transfected for 48 hours and labelled 
with biotin (500 µM) for 10 mins or 1 hour. DMEM media was then aspirated, washed twice with 
PBS, and fixed with 4% paraformaldehyde in PBS for 15 mins. After washing twice with PBS, 
cells were permeabilised with 0.2% (v/v) Triton X-100 for 10 minutes. Non-specific binding was 
blocked with 3% Normal Goat Serum in PBS for 60 minutes. MeCP2 was visualised using an 
antibody directed against 6-His (1:1000 dilution; Bethyl) or Streptavidin (1:1000 dilution; Sigma) 
for 60 mins. This was followed by washing three times with PBS for 5 minutes, staining with 
DAPI (2 µg/ml) for 5 minutes, and two further washes in PBS. Cells were then mounted onto 
microscope slides.  
 
Fluorescent microscopy was conducted on Leica DMIL LED. The software used to visualise was; 
Leica application suite af6000, version 4.0.0.11706. The pictures were analysed and processed 
in ImageJ (V 1.52a). 
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2.6 Transfection with TransIT-X2 reagent 
Cells for further experiments were transfected with TransIT-X2. NIH-3T3 cells were plated onto 
coverslips and/ or 6 well plates containing DMEM supplemented with FBS (10%) and 
penicillin/streptomycin (1%) 48 hrs before transfection so they were 70-80% confluent at time of 
transfection. Transfections were carried out with TransIT-X2 dynamic delivery system (Mirus) 
according to manufacturer’s instructions. Briefly, TransIT was left to warm to room temp and 
vortexed. Recommended concentration of DNA was diluted in recommended volume of serum 
and antibiotic free media. Recommended volume of TransIT was added to diluted DNA followed 
by gentle mixing and incubation at room temp for approximately 30 minutes. TransIT-DNA 
complexes were added to wells in a dropwise manner and plates incubated for approximately 30 
hours. 
 
2.7 Transfection efficiency of MeCP2-Turbo and MeCP2-miniTurbo in 
NIH-3T3 cells 
Transfection efficiency- the percentage of cells were transfected successfully, was calculated 
from cells transfected with MeCP2-TurboID and MeCP2-miniTurbo. Fluorescent imaging occurred 
at low magnification and multiple images were taken from different areas of the cover slips in 
order to calculate an average. It is of note that these were taken from areas of highest signal. 
Transfection efficiency was calculated as follows: 
 
 
TE= (number of true (transfected cells)/ number of live (DAPI stained) cells) x 100. 
 
2.8 Biotin labelling with MeCP2-TurboID and MeCP2-miniTurbo in 
NIH-3T3 Cells 
For labelling of transfected cells, I initiated biotin labelling approximately 36 hours following 
transfection. Biotin (Sigma) was diluted from a 100 mM stock (in dimethyl sulfoxide, DMSO), 
directly into serum containing cell culture medium to a final concentration 500 µM. Cells were 
treated with biotin and labelling was stopped after either 10 minutes and 1 hour by transferring 
the plates to ice and washing 4 times with ice cold PBS. For negative controls, I omitted the 
addition of biotin or used untransfected cells. 
 
2.9 Protein separation by SDS PAGE 
 
NIH-3T3 cells were plated, transfected and labelled with biotin as described above. Cells were 
subsequently detached from the flask through gently pipetting a stream of ice-cold PBS directly 
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onto the cells. Pellets were collected by centrifuging the resulting cell suspension at approximately 
500 x g for 5 mins. The supernatant was removed, and the pellet was lysed with 100 µl RIPA 
buffer (50 mM Tris pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% Sodium Deoxycholate, 1% Triton X-
100, 1 mM PMSF, and protease inhibitors (Sigma), by gentle pipetting and incubating at 4 ℃ for 
5 minutes. Lysates were clarified by centrifugation at 16,000 x g for 10 minutes at 4 ℃. Protein 
concentration was estimated using the Bradford Assay, consisting of Bradford Reagent (Sigma) 
and BSA as a standard, according to manufacturer’s guidelines. 
 
Loading samples were made to 25 µl and prepared by addition of 15 µl of the protein sample to 
6.25 µl of sample buffer (4x), 2.5 µl reducing agent (10x), followed by the addition of water to 25 
µl. Samples were boiled at 70 ℃ for 10 min prior to loading. Precision plus protein kaleidoscope 
was used as a ladder. 
 
SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) was performed on home-made gels (10%) 
containing 8% acrylamide, 0.375 M Tris pH 8.8 (resolving gel) or 0.127 M Tris 6.8 (Stacking gel) 
10% SDS, polymerised with 10% ammonium persulphate (APS) and TEMED. The electrophoresis 
occurred initially at 100V for 1.5 hours. 
 
2.10 Western Blotting 
 
Upon fractionation of proteins via SDS-PAGE, proteins were transferred to a nitrocellulose 
membrane using iBlot gel transfer device and iBlot gel transfer stacks (Invitrogen). The iBlot gel 
transfer stacks were constructed as per manufacturer’s guidelines. Transfer occurred over 8 
minutes. Blots were stained with Ponceau S solution (Sigma; 0.1% w/v in 0.5% acetic acid) for 5 
minutes and washed with 0.1% Tween 20 in Tris-buffered saline (TBS-T). The membranes were 
then blocked with 5% BSA in TBS-T for 1hr at room temperature. Blots were then stained with 
Streptavidin-HRP (1/3000 v/v; Thermo Scientific, N504) in 3% BSA in TBS-T for 1-2 hours at 4 
℃. For visualisation, the membrane was washed with 0.1% TBS-T and developed with Pierce 
ECL reagent. Imaging was carried out with the Invitrogen iBright FL1000 imaging system. 
 
2.11 Nuclear protein extraction 
 
NIH-3T3 cells were plated as before onto a 6 well plate. Cells were counted, suspended in 500 µl 
NE10 buffer (20 mM HEPES (pH 7.6), 10 mM KCl, 1 mM MgCl2, 0.1% Triton X-100 (vol/vol), 
protease inhibitors (Roche), 15 mM β-mercaptoethanol) and transferred into cold Eppendorf 
tubes. Following 15 min incubation on ice, the cell suspension was passed through a 25 gauge 
needle 10 times and incubated on ice for 20 minutes with intermittent vortexing. Centrifugation 
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then occurred at 4 ℃ for 5 min at 500g. Nuclei were washed in 500µl NE10 buffer and the 
suspension was passed through a 25 gauge needle 10 times then incubated at 25 °C for 5 min 
with 250 units benzonase (Sigma) per 10^7 nuclei. Centrifugation occurred at 4 ℃ for 10 min at 
500 x g before the nuclei were resuspended in 40 µl NE150 buffer (NE10 supplemented with 150 
mM NaCl). Incubation on ice occurred for 20 minutes with intermittent vortexing. Lysates were 
cleared by centrifugation at 4 ℃ at 16,000 x g for 20 minutes and the supernatant was transferred 
to new tubes as a nuclear extract. 
 
Samples were prepared for SDS-PAGE as determined previously and protein transfer onto a 
nitrocellulose membrane was carried out using an iBlot equipment and device according to 
manufacturer’s instructions. 
 
2.12 Probing for biotinylated proteins in the nuclear and cytoplasmic fractions 
 
The membrane was blocked with 3% BSA in TBS-T for 1 hour. (1/1000) in TBS-T containing 3% 
BSA and left to incubate for at least 1 hour. After washing 3 times with TBS-T, streptavidin labelling 
was done as before for 1-2 hours. 
 
2.13 Creating a stable NIH-3T3 cell line expressing MeCP2-TurboID and 
MeCP2-miniTurbo 
Genomic sequence analysis revealed the presence of a G418 resistance gene in MeCP2 vector 
(Fig 2.2). The stable transfection of NIH-3T3 fibroblasts with recombinant plasmid containing 
MeCP2-TurboID and MeCP2-miniTurbo was established by using TransIT-X2 and G418 
selection. Briefly, cells were split as before into 6 well plates 24 hours prior to transfection with 
TransIT-X2. Approximately 48 hours post transfection, media was replaced with media containing 
G418 (400 µg/ml) antibiotic. Media was replaced every 2-3 days and selection occurred over 1-2 
weeks. 
 
Once selection occurred, cells were plated onto 75 cm2 flasks with 15 ml media containing G418 
(400 µg/ml) and incubated at 37℃.
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Figure 2.2 Vector and recombinant plasmid containing the TurboID ligase are resistant to 
G418. Schematic highlighting that a) the vector contains a neomycin coding gene and that this is 
conserved in b) the recombinant plasmid of interest. The neomycin gene confers resistance to 
G418. This will be used for selection of cells containing the plasmid of interest. Made with 
Biorender  
 
2.14 Clonal stable cell line 
 
For clonal isolation, wells containing MeCP2-TurboID transfected cells were washed wish PBS, 
trypsinised, counted and diluted to 10 cells/ml. This diluted suspension (100 µl) was plated onto 
96 well plates. A few hours after plating, to allow for adhesion, wells containing only 1 cell were 
marked. Cells were left to grow from this single cell until >60% confluency was reached. Once 
adequate confluence was achieved in 96 well plates, cells in wells marked as having contained a 
single cell were trypsinised and cells plated onto cover slips in 24 well plates containing G418 and 
identically labelled 24 well plates. The latter was done as cells from a single well of the 96 well 
plate had to be imaged and some kept for maintaining the cell line. As the aim of this was to see 
if all cells in a particular well were expressing the proteins of interest, cells were left to adhere for 
24 hrs prior to treatment with biotin (500 µM) and Streptavidin-488 for fluorescent imaging. 
 
2.15 Cloning TBLR1 into MeCP2-TurboID 
 
To clone TBLR1 into the vectors MeCP2-EGFP and MeCP2-TurboID, genomic sequence analysis 
was carried out and revealed that TBLR1 did not contain any of the restriction sites seen in 
MeCP2-EGFP or those incorporated into MeCP2-TurboID and MeCP2-miniTurbo in this study. 
To this end, primers were hence designed with restriction sites for XhoI and BamHI in the correct 
orientation when considering the vectors (Table 2). Integrating XhoI and BamHI restriction sites 
into the primers, which already present in the vectors to be used, means that the same set of 
primers may be used for cloning TBLR1 into both of the vectors. 
A) B) 
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Table 2- Primers with embedded restriction sites for cloning TBLR1 
 
Primer Sequence 
F-Primer 1 
(Too short) 
 
R-Primer 2 
(Too short/out of 
frame) 
 
F-Primer 2 
(Correct length) 
5’-CGGCTCGAGATGAGTATAAGCAGTGATGAG-3’ 
 
 
 
 
5’-CGGGGATCCTTTCCGAGGGTC-3’ 
 
 
 
 
5’-CGGTAGCTCGAGATGAGTATAAGCAGTGATGAGG-3’ 
R-Primer 2 
(In frame) 
5’-CGACTAGGATCCACTTTCCGAGGGTCTAATACAC-3’ 
*The first set of primers used for cloning TBLR1 were too short and the reverse primer was out 
of frame. The second set of primers used for cloning have added bases and hence are long 
enough and in frame. 
 
2.16 PCR of TBLR1 
 
After designing primers with the chosen restriction sites, PCR of the insert was conducted 
according to standard protocol as highlighted at the beginning of this chapter. The conditions for 
the PCR amplification of TBLR1 were as follows: 
 
Table 3: Thermocycler settings for PCR 
 
 1 2 3 4 Cycles- 34x 6 7 
Temp ℃ 98 98 53 72 ////////////// 72 10 
Time (min) 2:00 0:15 0:30 1:30 ////////////// 2:00 ∞ 
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2.16.1 TBLR1 PCR Fragment purification 
 
Following PCR, PCR products were purified according to manufacturer’s (Qiagen) guidelines, and 
restriction digested using XhoI and BamHI. The bands of interest were gel extracted- MeCP2 at 
approximately 1500bp and TurboID and the rest of the plasmid at approximately 4900bp (Fig 2.3 
). 
 
A) 
 
 
PCR amplification Ligation 
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B) 
 
 
Figure 2.3 Schematic of cloning procedure of TBLR1. Genomic sequence analysis revealed 
that TBLR1 did not have appropriate restriction sites on the sequence of interest compared to 
MeCP2. PCR was conducted with primers consisting of restriction sites for XhoI and BamHI. This 
was a) followed by ligation of the vector (MeCP2-EGFP) and the insert (TBLR1). B) The same 
protocol may be used for the cloning procedure of the insert (TBLR1) into the vectors (MeCP2- 
TurboID and MeCP2-miniTurbo). 
 
 
 
2.16.2 PCR purification of TBLI 
The insert was amplified using PCR and the product was purified according to manufacturer’s 
(Qiagen) guidelines. Brief details of protocol are highlighted earlier in this chapter. 
 
 
2.16.3 Restriction digest and transformation 
The insert and vector plasmids were digested with restriction enzymes XhoI (NEB) and BamHI 
(NEB) for up to 2 hours to ensure full digestion. DNA was separated on a 1% TAE gel and the 
bands of interest were excised according to manufacturer’s (Qiagen) instructions. 
 
The concentration of purified DNA was measured using a nanodrop spectrophotometer and the 
vector (50 ng) was ligated with the insert DNA (30 ng) using T4 DNA ligase (NEB) and incubated 
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at 16ºC overnight to produce sticky ends according to the manufacturer’s protocol. XL Blue 
supercompetent cells (Agilent) were transformed with the ligated product according to 
manufacturer’s guidelines. Briefly, 100 µl cells were thawed on ice, 1.7 µl of β-mercaptoethanol 
was added to the cells and incubated on ice. Ligated DNA was added to the mix followed by 
further incubation for 30 minutes. Cells underwent standard heatshock at 42 for precisely 45 s 
before a short incubation on ice. Cell-DNA mix was added to preheated medium and tubes were 
incubated at 37°C for 1 hour with shaking at 225–250 rpm Transformed cells were plated onto 
kanamycin plates (30 µg/ml). 
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3- Results 
 
3.1 Generating MeCP2-TurboID and MeCP2-miniTurbo constructs 
 
To identify protein interaction networks for MeCP2, I sought to develop new tools that enabled 
proximity-based labelling of interacting proteins. These tools were generated by the fusion of a 
promiscuous biotin ligase (Branon et al., 2018) to the C-terminus of MeCP2. These tools should 
allow the biotinylation of proteins bound to, or located, within 10 nm of MeCP2 (Branon et al., 
2018). The biotin tag would then allow for the detection and purification of labelled proteins by 
taking advantage of the established strong biotin-streptavidin interaction. I generated two 
separate constructs whereby the two promiscuous biotin ligases, TurboID or miniTurbo (Branon 
et al., 2018) were fused to the C-terminus of MeCP2 using standard PCR-based cloning. 
 
To this end, I excised EGFP from an MeCP2-EGFP plasmid using the restriction enzymes BamHI 
and NoTI (Fig 2.1). TurboID, or miniTurbo, was then PCR amplified from another plasmid using 
primers designed to incorporate the restriction sites matching those in the MeCP2-EGFP plasmid. 
I then ligated the cut plasmid and PCR insert together using T4 DNA ligase. I confirmed the 
addition of TurboID or miniTurbo onto the C-terminus using restriction digestion and sequencing 
(Fig 3.1). 
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Figure 3.1 Generation of MeCP2-TurboID and MeCP2-miniTurbo constructs. A) Agarose gel 
electrophoresis of MeCP2-TurboID and MeCP2-miniTurbo after restriction digestion using NotI 
and BamHI. Arrows correspond to TurboID and miniTurbo, respectively. B) Sequencing 
chromatogram showing the 4 amino acid linker that joins MeCP2 and TurboID. The TurboID 
sequence is in-frame with the linker and MeCP2. 
 
3.2 MeCP2-TurboID and MeCP2-miniTurbo localise to the nucleus of NIH- 
3T3 cells. 
MeCP2 localises to the nucleus where it binds to methylated cytosines (Meehan et al.,1992). 
Previous studies have shown that the addition of EGFP to the C-terminus of MeCP2 does not 
affect it’s tissue or cellular localisation (Lyst et al., 2018; Schmid et al., 2008). I therefore wanted 
to determine whether the addition of TurboID or miniTurbo would affect the nuclear localisation of 
MeCP2. To this end, we transiently transfected MeCP2-TurboID, MeCP2-miniTurbo or MeCP2- 
EGFP into NIH-3T3 cells. We visualised the localisation of these proteins using an antibody 
against 6-histidine residues, since this tag was incorporated into the MeCP2 sequence. In 
agreement with previous work, I found that MeCP2-EGFP was exclusively localised to the nucleus 
and was concentrated in heterochromatin foci (Fig 3.2), regions that are enriched for methylated 
cytosines (Nan et al., 1996). Moreover, I found that the localisation of MeCP2-TurboID and 
MeCP2-miniTurbo is indistinguishable from that of MeCP2-EGFP (Fig 3.2). Thus, the addition of 
TurboID or miniTurbo does not affect the nuclear localisation of MeCP2. 
 
I next wanted to optimise the transfection protocol to ensure a high transfection efficiency, which 
would be required for future biochemical experiments. To this end, I transfected NIH-3T3 cells 
with increasing amounts of plasmid DNA. Overall, the TE ranged from 16-17% to 21-22% with 
TurboID and miniTurbo respectively. I found that the highest transfection efficiency (percentage 
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of cells expressing MeCP2) was obtained using 0.7µg DNA (Fig 3.3.2). Additionally, increasing 
the amount of DNA per well did not appear to significantly increase transfection efficiency, 
although the experiment must be repeated for adequate statistical analysis. 
 
 
 
 
 
 
 
 
Figure 3.2 MeCP2-TurboID and MeCP2-miniTurbo locate to the nucleus of NIH-3T3 cells 
NIH-3T3 cells were transfected with MeCP2-EGFP, MeCP2-TurboID, or MeCP2-miniTurbo. 
MeCP2 was visualised using an antibody directed against a 6-his tag incorporated into the MeCP2 
sequence. DNA was visualised using DAPI. Scale bar represents 20µm. 
44  
 
 
 
 
  
 
 
 
Figure 3.3. Average transfection efficiency was increased using similar amounts of MeCP2- 
TurboID and MeCP2-miniTurbo. Cells were Trans-IT X2 transfected with A) MeCP2-TurboID 
and B) MeCP2-miniTurbo. Cells were fixed with 4% paraformaldehyde, followed by incubation 
with rabbit anti-6 his primary antibody and anti-rabbit alexa-594 antibody. At least three images 
were obtained by fluorescent microscopy (40x) and an average transfection efficiency value 
calculated. 
 
3.3 MeCP2-TurboID and MeCP2-miniTurbo biotinylate nuclear proteins 
 
To examine the ability of MeCP2-TurboID and MeCP2-miniTurbo to biotinylate endogenous 
proteins we performed biochemical analysis of biotinylated proteins. To this end, I transfected 
NIH-3T3 cells with MeCP2-TurboID and MeCP2-miniTurbo and treated cells with exogenous 
biotin as before. Biotinylated proteins were detected using Alexa488-conjugated Streptavidin. In 
non-transfected cells, or transfected cells without exogenous biotin, fluorescent staining was 
mostly restricted to the cytoplasm (Fig 3.4.1). It is of note that a shift in biotinylated proteins from 
the cytoplasm to the nucleus was seen in untransfected cells following the addition of exogenous 
biotin (Fig 3.4.1). In 
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transfected cells treated with exogenous biotin, however, I observed robust nuclear fluorescence 
localised to heterochromatin foci (Fig 3.4.2, and Fig 3.4.3). 
 
 
 
 
Figure 3.4.1. Endogenous biotinylation in NIH-3T3 cells. Non-transfected NIH-3T3 cells were 
treated with biotin (500 µM) for either 0, 10 or 60 minutes. Biotinylation was detected using 
Streptavidin conjugated to Alexa488. Scale bar represents 20 µm. 
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Figure 3.4.2. MeCP2-TurboID biotinylates nuclear proteins. NIH-3T3 cells were transfected 
with MeCP2-TurboID. After 48 hours, cells were treated with biotin (500 µM) for either 0, 10 or 60 
minutes. Biotinylation was detected using Streptavidin conjugated to Alexa488. Scale bar 
represents 20 µm. 
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Figure 3.4.3. MeCP2-miniTurbo biotinylates nuclear proteins. Cells were transfected with 
MeCP2-miniTurbo. After 48 hours, cells were treated with biotin (500 µM) for either 0, 10 or 60 
minutes. Biotinylation was detected using Streptavidin conjugated to Alexa488. Scale bar 
represents 20 µm. 
 
3.4 Biotinylation by promiscuous ligases TurboID and miniTurbo 
 
Studies have shown that both TurboID and miniTurbo are able to biotinylate proximal proteins, 
but, however, differ in efficiency. To establish whether conjugated TurboID and miniTurbo are 
able to induce robust biotinylation, I transfected cells with MeCP2-TurboID and MeCP2- 
miniTurbo. Cell lysates were separated on an SDS-PAGE. Subsequently, proteins were 
transferred to a nitrocellulose membrane, and detected with Streptavidin-HRP. In non-transfected 
cells, or transfected cells without exogenous biotin, I detected the presence of at least two bands 
(Fig 3.5). The intensity of these bands was unaffected by the presence of the presence of 
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exogenous biotin, suggesting these are endogenously biotinylated proteins. In transfected treated 
with exogenous biotin, I observed increased biotinylation of proteins (Figure 3.5b). The increase 
in biotinylation was similar for MeCP2-TurboID and MeCP2-miniTurbo. Together, these data 
demonstrate that MeCP2-TurboID and MeCP2-miniTurbo lead to robust biotinylation of proteins 
in NIH-3T3 cells 
 
 
 
 
 
 
Figure 3.5. Biotinylation by MeCP2-TurboID and MeCP2-miniTurbo in NIH-3T3 cells. (A) 
Representative western blot showing biotinylated proteins in NIH-3T3 cell lysates from non- 
transfected cells and cells transfected with either MeCP2-TurboID or MeCP2-miniTurbo. Cells 
were incubated in the absence or presence of exogenous biotin (500 µM). Biotinylation was 
visualised using Streptavidin conjugated to HRP. (B) Quantification of Streptavidin-HRP signal 
intensity from western blots (n = 2). Bars represent mean ± sem. 
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3.5 Identifying protein distribution according to nuclear fractionization 
 
To further examine the nuclear localisation of biotinylated proteins, I prepared nuclear and 
cytoplasmic extracts from NIH-3T3 cells transfected with MeCP2-TurboID and MeCP2-miniTurbo. 
In the absence of exogenous biotin, I observe 2 bands in the cytoplasmic fraction and a single 
band in the nuclear fraction in cells transfected with both MeCP2-Turbo and MeCP2-miniTurbo 
(Fig 3.6). Contrastingly, I observed robust biotinylation in both the cytoplasmic and nuclear 
fractions of MeCP2-Turbo transfected cells (Fig 3.6). Overall, it can be seen that, again, 
biotinylation is more robust with MeCP2-TurboID than with MeCP2-miniTurbo(Fig 3.6). 
Biotinylation appears to occur predominantly in the cytoplasm, as highlighted by the presence of 
biotinylated proteins in the cytoplasmic fraction, in the presence of biotin. 
 
 
 
     Figure 3.6 Nuclear extraction of transfected NIH-3T3 cells. NIH- 3T3 cells were TransIT-X2 
transfected with MeCP2-TurboID and MeCP2-miniTurbo according to manufacturer’s instructions and left 
to incubate for a minimum of 24 hrs at 37℃. Wells were either treated with biotin (500 µM) for 60 minutes 
or no biotin was added. Nuclear extraction was conducted to separate the cytoplasmic and nuclear 
fractions of cells and proteins were separated on a 9% SDS-PAGE gel. Proteins were transferred via a 
western blot transfer. Membrane was blocked in 3% BSA in TBS- T for 1 hr. Blocking was followed by 
incubation in 1/3000 streptavidin-HRP in 3% BSA TBS-T overnight at 4 ℃. Untransfected cells were used 
as a control. Arrows highlight proteins detected at the expected molecular weight of MeCP2. 
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3.6. Selection using G418 
 
Cells were transfected with MeCP2-TurboID and MeCP2-miniTurbo, however, it was unclear 
whether biotinylation by transient transfection would provide sufficient signal for future pulldown 
assays. To address this, the next step was the production of a stable cell line using antibiotic 
selection. Sequence analysis highlighted that MeCP2 expresses a neomycin gene. In mammalian 
cells, when the neomycin gene is present, resistance to G418 is conferred by the neo gene in 
expression vectors which contain elements derived from transposons Tn601 or Tn5. The vector 
used in this project, pEGFP-N1_MeCP2 (WT; Addgene) contains aminoglycoside 3'-
phosphotransferase from Tn5, conferring resistance to neomycin, Kanamycin and G418 (Fig 2.3a) 
This was also conserved in the conjugated plasmid (Fig 2.3b). Post transfection, cells were treated 
media containing G418. Only cells containing the plasmid which conferred resistance to G418 
would hence be able to grow. After approximately 2 weeks, when selection was considered to be 
complete, cells were plated onto cover slips and treated with biotin followed by streptavidin-488 
and visualised. 
 
 
Selection appears to have been successful. Transfected NIH-3T3 cells were able to grow in the 
G418 containing media, indicating successful incorporation of the plasmid of interest (Fig 3.7). 
Additionally, fluorescent imaging showed no presence of live untransfected cells after 
approximately 14 days. Untransfected cells were unable to survive in G418 containing media 
when treated under the same conditions as transfected cells (Fig 3.7). This reinforces the fact that 
only cells containing the plasmid of interest would be present after the selection period. 
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Figure 3.7 selection of cells containing MeCP2-TurboID and MeCP2-miniTurbo. Antibiotic 
selection of NIH-3T3 cells was created with cells TransIT-X2 transfected with MeCP2-TurboIDand 
MeCP2-miniTurbo. Cells were plated in G418 (400 µg/ml) containing media and media was 
replaced every 2 days. Cells were plated onto cover slips, treated with exogenous biotin (500 µM) for 
1 hr followed by fixing with 4% parafolmadehyde and incubation with streptavidin-488 (1/1000). 
Visualisation occurred at 40x magnification. Scale bars represents 50 µm. 
 
3.7 Generating a stable cell line containing MeCP2-TurboID 
To overcome limitations caused by low transfection efficiencies, I generated a stably transfected 
cell line for MeCP2-TurboID derived from a single cell. The selection was performed using G418 
(400 µg/ml). 
 
 
The first round of clonal selection revealed a mix of cells containing the protein of interest and not 
containing the protein of interest. This was established by treatment with biotin followed by 
incubation with streptavidin. Cells containing MeCP2-TurboID would biotinylate nearby proteins 
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and travel to the nucleus, as seen in Figure 3.8, whereas those without MeCP2-TurboID 
incorporated would not be able to biotinylate proteins. 
 
 
After considering which wells contained the highest percentage of protein expressing cells, these 
were left to grow and another round of monoclonal selection was conducted. To confirm stable 
cell line generation, we treated cells with exogenous biotin (500 µM) for 60 minutes and examined 
biotinylation using Streptavidin-488. I show that 100% of cells contained robust nuclear 
biotinylation (Figure 3.8). I thus confirmed the generation of a stable cell line. 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 A stable cell line containing MeCP2-TurboID was created. NIH-3T3 cells 
transfected with MeCP2-TurboID. This was followed by treatment with biotin (500 µM) and 
Streptavidin-488 for fluorescent visualisation. Scale bar represents 25µm. 
 
3.8 Cloning TBLR1 into MeCP2 
 
3.8.1 Integration of restriction sites into TBLR1 
Primers were designed containing XhoI and BamHI restriction sites on the forward and reverse 
primers respectively. Post PCR and PCR purification, a restriction digest using XhoI and NotI 
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restriction enzymes was conducted on the insert plasmid, TBLR1, as well as the vector plasmids 
MeCP2-EGFP and MeCP2-TurboID (Fig 3.9). The presence of the amplified insert DNA (TBLR1) 
band is seen at 1.5Kb and the bands present at approximately 5kb and 1.5kb in the vector 
highlight successful restriction digest. 
 
 
Cloning of TBLR1 was attempted into WT MeCP2 (MeCP2-EGFP) so that, if successful, 
fluorescence microscopy of NIH-3T3 cells transfected with this construct would be used to confirm 
successful localisation of this protein. 
 
 
 
 
 
Figure 3.9 Restriction digest of TBLR1 PCR fragment and MeCP2-EGFP and MeCP2- 
TurboID plasmids. Representative agarose gel showing TBLR1 PCR fragment and the vector 
plasmids, MeCP2-EGFP and MeCP2-miniTurbo after restriction digestion with BamHI and XhoI. 
White arrow shows the cut plasmid; hollow arrow shows the cut MeCP2 fragment.
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4-Discussion 
 
4.1 Summary 
This study applied a recently developed proximity labelling approach to the identification of 
MeCP2 protein interaction networks. Proximity labelling involves the covalent tagging of biotin to 
proximal interacting proteins of MeCP2 using a promiscuous biotin ligase. This methodology 
overcomes a number of issues with other protein-protein interaction approaches (Kim and Roux, 
2016). Using two efficient promiscuous biotinylating enzymes derived from BirA, TurboID and 
miniTurbo, I attempted to provide evidence that proximity labelling is a feasible technique for 
finding interacting proteins of MeCP2. 
 
 
Other aims of the study, which comprised confirming existing interactions and cloning TBLR1 into 
MeCP2-TurboID, were not achieved in the time frame of this project. This is further discussed in 
the limitations and future directions (see section 4.8 and 4.8.1). 
 
4.2 MeCP2-TurboID and MeCP2-miniTurbo localise to heterochromatin 
Prior studies have shown that biotin labelling may be carried out in different cell organelles 
(Branon et al.,2018). As MeCP2 is a nuclear protein, it was important to establish whether 
transfecting the protein’s C-terminus hindered its ability to localise to heterochromatic foci. In this 
study I demonstrate that the promiscuous ligases, TurboID and miniTurbo (Branon et al., 2018) 
can be used to detect nuclear proteins in close proximity to MeCP2. Upon expression in NIH-3T3 
cells, I show that tagging TurboID and miniTurbo to the C-terminus of MeCP2 do not affect the 
protein’s nuclear localisation (Fig 3.2). This finding is in line with that of previous studies in mice, 
in which C and N termini alterations have been shown not to interfere with the functionality of the 
protein. When mice expressed the minimal protein, consisting of the two main domains, the MBD 
and NID, they survived for over a year with only mild symptoms (Tillotson et al.,2017). The critical 
regions of the protein, the MBD and NID were deliberately avoided when choosing insertion sites 
for TurboID and miniTurbo. 
 
 
Additionally, previous studies have shown that fusing a Gal4 binding domain to the N-terminus of 
MeCP2 and co-transfecting this with a Gal4-binding site fused to a luciferase reporter gene, can 
quantify any changes in MeCP2-mediated repression of the reporter (Ebert et al., 2013; Lyst et 
al., 2013). I should perform a similar repression assay using MeCP2-TurboID and MeCP2- 
miniTurbo. Upon providing evidence that transcriptional repression is not affected, I can 
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confidently state that the function of MeCP2 is not abrogated upon fusion with TurboID or 
miniTurboID. 
 
 
4.3 Transfection efficiency 
Having established successful transfection, optimisation of (TE) was required in order to obtain 
enough signal on future western blots and pull downs. Previous studies have evaluated various 
commonly used non-viral transfection reagents with regards to their ability to deliver plasmid DNA 
and siRNA into cultured mouse cells (Tamm et al.,2016). TransIT-X2 has been previously found 
to be the most efficient reagent for transfection of adherent mouse cells (Tamm et al.,2016). 
Additionally, TransIT-X2 is widely considered an advanced, non-liposomal and low toxicity 
transfection reagent (Mirus protocol) and was hence chosen for transfections in this study. 
Transfections were optimised with differing concentrations of DNA. My data show that TE, using 
the TransIT-X2 system was highest when 0.7 µg DNA were present in each well (Fig 3.3). This is 
higher than that suggested by the manufacturers. This pattern can also be seen in cells 
transfected with MeCP2-miniTurbo where the highest TE was also achieved by transfection using 
0.7 µg DNA per well (Fig 3.3). Despite this, efficiencies observed in this study were lower than 
expected when considering previous literature. TransIT transfection reagents have previously 
yielded efficiencies as high as 40% in NIH-3T3 cells, as determined by the number of EGFP 
expressing cells (Hayes., 2010). Considering this, the TE achieved in this study appears relatively 
low. It is of note that transfection in the C-terminus of MeCP2 has not been done before using 
constructs such as TurboID and miniTurbo, thus making direct comparisons difficult and thus the 
difference between this study’s findings and previous study’s findings may have occurred by 
chance.  
 
 
Additionally, in this instance, only the DNA concentration was increased. While it is expected that 
increasing DNA concentration would increase transfection, it is surprising that the maximum TE 
was not achieved with the highest DNA concentration. This decrease in TE when using a higher 
DNA concentration could be due to inefficient DNA-TransIT complex formation. While DNA 
concentrations were increased, transfections were done with TransIT added to 2 µl/µg DNA. In 
future, to further maximise TE, transfections with differing amounts of TransIT from 2 µl/µg DNA 
to 6 µl/µg DNA should be done and TE recalculated. A higher TransIT concentration is likely to 
aid the formation of DNA-TransIT complexes and thus result in increased TE. 
 
 
It is also likely that increased cell confluency could hinder transfection, as the densely packed 
cells could make the transfection reagent less able to access all cells. The TransIT reagent is 
recommended for transfection at 80% confluence (Mirus Protocol). The enzymatic dissociation 
involved in successful transfection induces the shaving of membrane-associated factors, 
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including glycoproteins with highly sulphated glycosaminoglycan (GAG) polysaccharide chains 
(Vogel., 1978). The large number of sulphate groups makes the chains negatively charged, 
anionic, and hence allows interaction with various positively charged substrates. Previous studies 
have shown that cell surface GAGs interact with transfection reagent polymers and liposomes 
and inhibit cation-mediated gene transfer (Ruponen et al.,2004). Attempting transfection at 
different levels of confluency would hence help determine the optimal density to maximise 
transfection reagent access to the cell surfaces. 
 
 
DNA purity may be an additional factor hindering the attainment of maximum TE using TransIT- 
X2. A Qiagen-Midiprep kit was used to extract DNA for transfections. While this contains additional 
wash steps, the presence of endotoxins may still remain, which may hinder the formation of DNA-
TransIT complexes, and hence reduce maximum TE. In the future, DNA extraction should be 
done using an endotoxin removal kit. Additionally, optimisation of TE could be continued by using 
different amounts of TransIT-X2 reagent. The latter is likely to aid achievement of optimal DNA-
TransIT complexes and thus maximise TE achieved. 
 
 
To summarise, my data reveal that at every concentration, the TE with both constructs was similar. 
A decrease in TE is seen in both of these constructs at higher concentrations. The similar pattern 
of TE for both constructs is expected as TurboID and miniTurbo have similar molecular weights 
of 35 kD and 28 kD respectively (Branon et al.,2018). It is important to note that this experiment 
was conducted once for each construct and a more accurate statistical comparison would be 
achieved with at least 2 more repeats and that, indeed, this finding may not be reproducible. 
 
4.4 MeCP2-TurboID and MeCP2-miniTurbo biotinylate proteins in NIH-3T3 
cells 
To evaluate the effectiveness of MeCP2-TurboID and MeCP2-miniTurbo in biotinylating nuclear 
proteins, I transiently transfected NIH-3T3 cells with exogenous biotin. I then assessed 
biotinylation by isolating cell lysates separating protein lysates by SDS-PAGE and examining 
Streptavidin binding to Western blots. I found that found that both MeCP2-TurboID and MeCP2- 
miniTurbo led to a robust increase in the number of Streptavidin-reactive bands. No additional 
biotinylation occurred upon the addition of biotin in untransfected cells, suggesting any changes 
are solely a result of biotin ligase activity. MeCP2-TurboID displayed a higher efficiency to 
biotinylate than MeCP2-miniTurbo when supplemented with biotin. Therefore, TurboID is more 
likely to abundantly enrich interacting proteins of MeCP2 when labelling. Both biotin ligases 
displayed activity in the absence of exogenous biotin. This is likely due to endogenous biotin in 
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the culture media. We performed these experiments in duplicate. In future experiments, we should 
perform at least one more replicate to allow statistical comparison between MeCP2-TurboID and 
MeCP2-miniTurbo. 
 
However, TurboID displayed higher basal activity than MeCP2-miniTurbo without biotin addition. 
Thus, TurboID cannot be temporally controlled as easily as miniTurbo. These findings suggest 
that TurboID has higher efficiency but lacks the ability to be controlled, unlike miniTurbo, is 
concurrent with previous findings (Branon et al., 2018). The heightened activity of TurboID when 
using endogenous biotin, could sacrifice the specificity of labelled proteins once exogenous biotin 
is added. If TurboID has biotinylated a number of proteins prior to the addition of exogenous biotin, 
more proximal acceptor sites will be saturated when biotin is added. Therefore, upon exposure to 
exogenous biotin, more distal, potentially unspecific, acceptors will be labelled. This is similar to 
the previous demonstration that specificity is reduced if biotinylation is allowed for a prolonged 
period (Branon et al., 2018). Hence, miniTurbo may be a better enzyme in labelling specific 
interactors of MeCP2. 
 
Here, I added biotin for 1 hour or 10 mins. When untransfected cells were exposed to biotin for 
either 10 minutes or 60 minutes, biotinylated proteins could be seen both in the nucleus and the 
cytoplasm. It is of note that when biotinylation occurred for 60 minutes, there was a shift in the 
biotinylation signal in untransfected cells. This suggests that longer exposure of untransfected 
cells to biotin leads to a reduction in biotinylation signal in the cytoplasm and an increase in the 
nucleus. For biotinylation labelling prior to western blotting, 60-minute labelling was used in order 
to come out with stronger blots and ensure the labelling of the largest quantity of MeCP2 
interactions. It has been previously suggested that labelling for 60 minutes was less specific than 
that for 10 minutes (Branon et al.,2018). In future experiments, 10-minute biotin labelling would 
reduce the likelihood of unspecific interactors. 
 
Indeed, miniTurbo is less stable than TurboID, which may be giving rise to the differing 
biotinylation activities found (Branon et al., 2018). This experiment should be repeated, and the 
western blot probed with an antibody specific to a haemagglutinin (HA) tag, found in the TurboID 
and miniTurbo constructs. The activity can then be quantified with respect to the expression of 
the ligase (HA-tag intensity), to understand the efficiency of each ligase. There are two strongly 
biotinylated bands at approximately 70 kDa and 110 kDa in every condition. These are likely 
endogenously biotinylated proteins, not interactors of MeCP2. 
 
Our experiments revealed the presence of biotinylated proteins in untransfected NIH-3T3 cells. 
Using Alexa488-conjugated Streptavidin, we found that these endogenously biotinylated proteins 
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are predominantly localised to the cytoplasm in the absence or presence of exogenous biotin. In 
contrast, the addition of exogenous biotin led to a robust increase in nuclear biotinylation in cells 
transfected with MeCP2-TurboID or MeCP2-miniTurbo. 
 
 
4.5 MeCP2-TurboID and MeCP2-miniTurbo biotinylate nuclear proteins 
To summarise, MeCP2 has affinity for methylated DNA and hence I  would expect to  see it  in the 
nucleus post successful transfection.  On the other hand, the proteins detected in the nucleus 
after transfection with MeCP2TurboID/miniTurbo could indeed be nuclear proteins and be 
biotinylated and  hence also transported to the nucleus. Both TurboID and miniTurbo were capable 
of biotinylating proteins after just 10 minutes (Fig 3.4.2-3.4.3). This result is expected as it has 
been previously found that biotinylation by unconjugated TurboID and miniTurbo can be seen after 
10 minutes in the nucleus, mitochondrial matrix, ER lumen and ER membrane (Branon et 
al.,2018). These data suggest that biotinylation using the above constructs in the future can be 
done significantly more efficiently than before with BioID. These data also suggest that both ligases 
may be transfected into the C-terminus of the protein without significant decrease to biotinylating 
efficiency. The latter opens avenues for the investigation of molecular interactions of various 
proteins. 
 
 
We showed that proteins biotinylated by MeCP2-TurboID and MeCP2-miniTurbo (when fused to 
MeCP2), are located in the nucleus, particularly at the heterochromatin, following the addition of 
biotin. The localisation of these proteins is in the same regions we found MeCP2 to localise. This 
suggests biotinylation of proteins is targeted within close proximity to MeCP2. We cannot be sure 
whether these biotinylated proteins are specific interactors of MeCP2, but it is promising that 
proteins appear to tightly co-localise to the MeCP2 position. We also showed that both 10 minutes 
and 1 hour of biotinylation is sufficient for MeCP2-TurboID and MeCP2-miniTurbo to produce 
enough biotinylated proteins for an intense immunofluorescent signal. Therefore, it may well be 
feasible to carry out biotin labelling for just 10 minutes. 
 
In the absence of exogenous biotin, I noticed the presence of endogenously biotinylated proteins 
in the cytoplasm and note their absence from the nucleus. To remove these proteins during 
biochemical experiments, I prepared nuclear and cytoplasmic extracts from NIH-3T3 cells 
transfected with MeCP2-TurboID. I found the presence of two endogenously biotinylated protein 
bands in the cytoplasmic fraction. I also found a weak non-specific biotinylation band in the nuclear 
fraction. Whether this is a truly nuclear protein remains to be determined since I used a somewhat 
crude preparation of nuclei. Future experiments should use a more stringent preparation of 
neuronal nuclei. 
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Based on the nuclear localisation of MeCP2-TurboID and MeCP2-miniTurbo seen during earlier 
stages of this project, it was expected that nuclear extraction would also reveal the presence of 
biotinylated proteins in the nuclear fraction. Accordingly, nuclear extraction reveals a band at 
approximately 75kDa in the nuclear fraction of NIH-3T3 cells (Fig 3.6). Considering that 
endogenous MeCP2 is 72kDa, then the recombinant protein (MeCP2-Turbo or MeCP2-
miniTurbo) should have also been biotinylated, which would give a MW weight band in transfected 
cells.Additionally, the fact that MeCP2 has affinity for methylated DNA, present in the nucleus, 
means a band at the above molecular weight is expected in the nuclear fraction. This affinity for 
methylated DNA would lead to the proteins localising to heterochromatic foci in the nucleus. 
Evidence suggests the redundancy in the role of a nuclear localisation signal in this process. 
MeCP2 may locate to the nucleus due to its affinity to DNA alone, without the need for importins 
such as KPNA3 and KPNA4 (Lyst et al.,2018), which reinforces the reason for a single band in 
the nuclear fraction. However, while a recent paper has reinforced the redundancy of KPNA3 and 
KPNA4, another importin, KPNA1, has been implicated in the process of MeCP2 nuclear 
localisation. Knockouts of KPNA1, reduced MeCP2 nuclear localisation (Panayotis et al.,2018). 
However, the same was not found for knockouts of KPNA3 and KPNA4 (Panayotis et al., ,2018). 
More research is needed to solidify the role of KPNA1 and indeed other importins in MeCP2 
nuclear localisation. 
 
 
Additionally, a protein of approximately 75kDa is also detected in the nuclei of untransfected cells 
(Fig 3.6). There are two main possible explanations for this. This finding may have arisen if NIH- 
3T3 cells produce their own MeCP2. Despite being most abundantly in the brain, MeCP2 is 
present in most tissues and cell types (Coy et al., 1999; Shahbazian et al.,2002; Akbarian et 
al.,2001). If this is the case, it is possible that the cell’s own MeCP2 may be detected in a western 
blot analysis. Secondly, data may be depicting another protein of a similar molecular weight to 
that of MeCP2. While biotinylation detectable by western blot can be seen, which would likely only 
occur in the presence of MeCP2-TurboID and MeCP2-miniTurbo, probing the membrane with a 
specific antibody against MeCP2 would be shed light on the identification of the protein in the 
nuclear fraction of my analysis. 
 
My data reveals a protein of approximately 75kDa is also present in the in the cytoplasmic fraction 
of transfected cells. This may arise due to the fact that proteins, including MeCP2, are produced 
in the endoplasmic reticulum, a cytoplasmic organelle. Additionally, biotinylated proteins can be 
seen in the cytoplasmic fraction of cells transfected with MeCP2-TurboID despite the fact that 
MeCP2 is a nuclear protein. This finding was unexpected as one of my previous experiments 
highlighted biotinylated proteins can be seen localised the nucleus of transfected NIH-3T3 cells 
post addition of exogenous biotin (Fig 3.4.2-3.4.3). This may occur due to numerous reasons. 
After MeCP2 production, it may still be present in the cytoplasm before entering the nucleus, 
explaining why proteins would be biotinylated in this fraction. Moreover, it is possible that MeCP2 
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interacts with importins in the cytoplasm but not in the nucleus. This explanation agrees with the 
hypothesis that importins may act as chaperones. Importins circulate between nucleus and 
cytoplasm and transfer cargo molecules from one side of the nuclear envelope to the other (Jäkel 
et al.,2002). At the nucleoplasmic side of the NPC, where Ran binds to the importin, the 
importin/substrate complex dissociates, leading to the importin being is re-exported from the 
nucleus to the cytoplasm (Jäkel et al., 2002). If this is the case, these interactions would be seen 
in the cytoplasmic fraction of transfected cells.  
 
The slow diffusion kinetics of MeCP2 (Piccolo et al.,2019) may also shed light on the reason for 
the presence of biotinylation in the cytoplasm of transfected cells, particularly those transfected 
with MeCP2-TurboID. It has been identified that MeCP2 has strikingly slow diffusion dynamics 
compared to molecules such as Sox2 or TBP molecules (Piccolo et al.,2019). This slow rate of 
diffusion may hence mean that the protein is in the cytoplasm for a longer amount of time, allowing 
for biotinylation to occur here. It is important to consider that the new protein made containing the 
biotinylating ligases TurboID and miniTurbo may have an increased weight compared to the WT 
protein. Considering that the MeCP2-WT is at the limit for free diffusion through the nuclear pore 
(Wang and Brattain, 2007) due to its elongated shape (Klose and Bird, 2004) it may be that larger 
conjugated plasmids may have a further reduced rate of diffusion and hence are retained in the 
cytoplasm for longer. The possibility that the conjugated construct could weigh more and diffuse 
even slower cannot be excluded. Future experiments regarding the cellular kinetics of conjugated 
MeCP2 would be beneficial. 
 
 
4.6 Stable cell line containing MeCP2-TurboID and MeCP2-miniTurbo 
Plasmid vectors designed for stable expression of foreign and recombinant proteins often contain 
two distinct expression cassettes, or promoters; one for the protein of interest and another for the 
selection marker, such as G418 (Hobbs et al.,1998). Transfected cells are selected based on the 
acquired resistance to a specific drug, such as G418 (Hobbs et al.,1998). Using this basis for 
selection, in this study, I successfully selected for cells containing MeCP2-TurboID and MeCP2- 
miniTurbo. Figure 3.7 shows that no untransfected cells are present in wells which were in G418 
media. The latter is expected due to the fact that untransfected cells would not have the G418 
resistance gene present in the recombinant plasmids consisting of MeCP2 and hence would not 
survive in G418 containing media. Conversely, cells transfected with MeCP2-TurboID and 
MeCP2-miniTurbo are highlighted by their biotinylation ability, conferred by the presence of the 
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biotinylating ligases TurboID and miniTurbo in the plasmids of interest taken up by the transfected 
cells. Successful integration of the recombinant plasmid in transfected cells would confer 
resistance to G418 and, in theory, integration of the biotinylating ligase. 
 
 
Non protein expressing cells can be seen in wells containing cells transfected with MeCP2- 
TurboID and MeCP2-miniTurbo (Fig 3.7). As the transfected cells express drug resistance but do 
not express the protein of interest, they are false positives (Hobbs et al.,1998). In this case, it is 
likely that cells may have successfully taken up the plasmids of interest, allowing survival and 
growth in media containing G418, but are not expressing the proteins of interest. It is possible that 
the transfected circular plasmid will be linearised by a random cut within the cell and it might be 
possible that sensitive parts of the plasmid such as the resistance gene or the gene of interest are 
destroyed upon linearisation. This means that if the resistance gene and the gene of difference are 
under different promoters, as is the case in the recombinant plasmid in this project, the resistance 
gene may be incorporated into the cell’s genome without the incorporation of the protein of 
interest. Cells containing the resistance gene would survive in G418 media due to the G418 
resistance gene present in the plasmid constructs without necessarily possessing the protein of 
interest. In the future, linearising the construct via digestion with BamHI and XhoI prior to 
transfection would aid more efficient incorporation of the protein of interest; the linearisation would 
mean that if the resistance gene is incorporated into the plasmid, so would the protein of interest. 
Additionally, the use of a bicistronic vector could also be employed for more efficient incorporation 
of the plasmid of interest. Bicistronic vectors are often used to express recombinant proteins at 
higher levels. The vital aspect of bicistronic cloning is the fact that an internal ribosome entry site 
(IRES) is involved. When an IRES segment is between two reporter reading frames in a eukaryotic 
mRNA molecule it is able to drive translation of the downstream protein coding region independent 
of the 5'-cap structure bound to the 5' end of the mRNA molecule (Pelletier and Sonenberg., 
1988). In such a model, both proteins are produced and expressed in the cell. 
 
4.7 Cloning TBLR1 into MeCP2 
To the best of my knowledge, this study highlights the first attempt of cloning TBLR1 into MeCP2- 
EGFP and MeCP2-TurboID. Additionally, using the ligase containing vectors already designed as 
part of the project means that when carrying out biotin labelling in future experiments, protein 
interactions of MeCP2 and those of TBLR1 could be compared as they would have not been 
confounded by the use and hence protein interactions of a different vector. The latter would enable 
for more robust comparison of the interactors of MeCP2 and TBLR1 and potentially shed light on 
the function and importance of the MeCP2-TBLR1 interaction. 
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Sequence analysis highlighted the need to incorporate XhoI and BamHI restriction sites in the 
primers for amplification of the insert. The first set of primers designed were too short, with only 
20 bases to anneal to the DNA fragment of interest (Table 2). The latter reduced is likely to reduce 
specificity and hence means this short primer is more likely to be able to bind elsewhere with 
complementary base pairs other than the insert fragment of interest. The latter would mean that 
the ligation would not be successful. To correct this, I designed primers that are longer and with 
more bases at the beginning to aid efficient annealing. 
 
 
The reverse primer had an odd number of bases. This would lead to a lack of biotinylation when 
cloned with TurboID as the sequence coding for the biotinylating ligase would be out of frame due 
to the presence of odd number of bases in the linker between TBLR1 and TurboID. To correct this 
another base was added to the linker. 
 
 
I was able to successfully amplify the insert DNA using the primers designed and use restriction 
digest with BamHI and XhoI to cut the insert and vector DNA. Bands at approximately 1.5kb, the 
size of the TBLR1 insert, indicate that the PCR reaction and the primers used in this successfully 
amplified an insert of the correct size. Additionally, restriction enzymes were able to use the 
complimentary restriction sites to cut the MeCP2-EGFP and the MeCP2-TurboID plasmids, 
resulting in bands of the expected length at the restriction digestion stage. The latter suggests 
success of the cloning procedure until the restriction digestion. 
 
 
Despite the above amendments to the primers and thus cloning procedure, I was unable to 
successfully clone TBLR1 into MeCP2-EGFP and MeCP2-TurboID, as observed by lack of 
transformants post competent cell transformation and overnight incubation at 37ᵒC under 
antibiotic selection. There could be a number of reasons for this. One possibility is that the ligation 
was inefficient. Ligation was attempted for different durations of time- overnight at and for 2 hrs 
and this did not yield success. 
 
 
One other cloning avenue to pursue could be to avoid the use of restriction sites altogether and 
use Sequence Ligation Independent Cloning (SLIC; see 4.8). 
 
4.8 Limitations and future work 
While the biotinylating efficiency of BioID has been compared to that of Turbo and miniTurbo, in 
this study the biotinylating efficiency of conjugated Turbo and miniTurbo have not been compared 
to conjugated BioID. It would be interesting to see if conjugating BioID has any effect on its 
biotinylating efficiency and to check if the differences in biotinylating efficiency seen by Branon et 
al in unconjugated forms of the ligases are reiterated in its conjugated forms in mammalian cells. 
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A stable cell line was generated for MeCP2-TurboID but not MeCP2-miniTurbo. MiniTurbo has 
been suggested as the primary ligase to use when highlighting specific interactions is a priority. 
A stable cell line of miniTurbo may be useful to produce and conduct biotinylation experiments in 
the future and can be achieved in an identical way as to that used for MeCP2- Turbo in this project; 
first by transfecting and seeding into individual cells followed by selection with G418. 
 
Previous studies have highlighted various interactors of MeCP2, with some of the major ones 
being NCOR, SMRT, TBLR1 and HDAC3 (Kruusvee et al.,2017; Li et al.,1997; Codina et 
al.,2005). Post successful establishment of a stable cell line with both constructs, MeCP2-TurboID 
and MeCP2-miniTurbo, a pulldown assay could be performed. The interaction between biotin and 
streptavidin isolates the interacting proteins, thus, this interaction could be used to confirm if these 
proteins interact with MeCP2. To do this, streptavidin beads could be used to enrich the proteins 
biotinylated by TurboID or miniTurbo. Following this, peptides would be formed via on-bead 
digested on the protein prior to being isotopically tagged via a tandem mass tagging for the 
quantification of the relative amounts of proteins tagged by TurboID and miniTurbo. Liquid 
chromatography-tandem mass spectrometry analysis would be used to highlight the protein 
interactome for the proteins biotinylated by TurboID and miniTurbo conjugated MeCP2, aided by 
the stable nature of the proteins. This interactome would be analysed for the co-complexes known 
to be associated with MeCP2, and hence used to identify novel MeCP2 interactions. Comparisons 
of protein co-complexes would be done by using established databases such as RefSeq. 
Identifying novel interactions with, and confirming, rebuking, or quantifying established 
interactions, would be an initial step for a clearer picture of the biological purpose of MeCP2 to be 
constructed. 
 
In this study, both MeCP2-TurboID and MeCP2-miniTurbo were able to label biotinylated proteins 
in as little as 10 minutes or 60 minutes. Conjugating Turbo and miniTurbo did not alter the 
biotinylation efficiency of the constructs. While I have shown that this short time frame continues 
to be sufficient for biotinylation to occur with a conjugated , an interesting avenue to pursue could 
be to enable biotinylation to occur for longer and various periods of time, such as 16 hrs, followed 
by a pull down assay of the biotinylated proteins for mass spectrometry analysis, as highlighted 
above. This would allow us to detect any differences in proteins biotinylated by the new constructs 
when biotinylation is allowed to continue for different amounts of time. 
 
 
We used a mouse fibroblast cell line, NIH-3T3, for ease of use and the heterochromatin foci that 
form following DAPI staining. This cell line may not be particularly relevant for understanding 
interactions when considering RTT. MeCP2 is expressed very highly in the brain, therefore may 
have different functions and interactions with proteins in neurons. We should therefore repeat our 
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experiments using neuronal cell lines as this will likely elucidate interacting proteins of MeCP2 
more relevant to brain functionality. 
 
Changes in MeCP2 interactions in RTT can be assessed using this methodology. Fusing TurboID 
or miniTurbo to MeCP2 with an RTT-causing mutation, such as MeCP2T158M or MeCP2R306C, can 
identify interactions lost due to mutation when compared to wild-type MeCP2. This may be applied 
to both neuronal cells and mouse models of RTT-syndrome. Creation of transgenic mice 
containing a mutant MeCP2 fused to TurboID or miniTurbo will be able elucidate pathologically 
relevant changes in interactions at an organismal context rather than just in cell culture. This 
approach may also be undertaken using cells from RTT patients. The ability to reprogramme 
somatic cells into iPSCs from RTT patients and differentiate them into neurons, can allow the use 
of proximity labelling to observe interactions in human cells carrying different RTT-causing 
mutations. 
 
A potential constraint needing to be addressed in mouse models is loss of viability or health upon 
biotin ligase expression. It was found that Drosophila and C. elegans were less viable when 
TurboID and miniTurbo were expressed, most likely due to biotin starvation (Branon et al., 2018). 
This may present mice with health defects as a result of biotin deficiency. To overcome this, we 
could supplement the mouse diet with increased biotin as done previously (Johnson et al., 2017). 
 
 
A SLIC method of cloning could be used to clone TBLR1 into TurboID and miniTurbo. SLIC mimics 
homologous recombination by using exonuclease, such as T4 DNA polymerase in the absence 
of dNTPs, for generation of single stranded overhangs are annealed in vitro either in the presence 
or absence or and transformed into cells (Figure 4.1; Li and Elledge., 2012). RecA may be used 
to promote homology searching and annealing in vitro but it need not be used of sufficient amounts 
of DNA are present (Li and Elledge., 2012). Importantly, the homology need not be perfect for 
SLIC, as stretches of nonhomology on the ends of annealed sequences are removed upon 
transformation in E. coli (Figure 4.1; Li and Elledge., 2012). In addition, excess excision is well 
tolerated, providing an increased margin of error in fragment preparation unless fragments are 
very small (Li and Elledge., 2012). SLIC is hence likely to be able to overcome limitations 
encountered in the restriction and ligation dependent method used in this project. 
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Figure 4.1 In vitro homologous recombination using SLIC. Schematic highlighting the 
process of producing recombinant DNA using SLIC. Created using Biorender and adapted from 
Li and Elledge, 2012. 
 
 
Cloning of TBLR1 into the vector plasmid in order to establish its interaction with MeCP2 could 
provide an interesting avenue of research. Additionally, cloning TBLR1 into Turbo and miniTurbo 
containing plasmid would enable the determination of proximal proteins by biotinylation and thus 
possibly confirm the interaction between TBLR1 and MeCP2 as well as identify new interactions. 
 
4.8.1 Alternative way of addressing and validating protein interactions 
found for MeCP2 
 
Once mass spectrometry of proteins biotinylated by stable cell lines containing MeCP2-TurboID 
and MeCP2-miniTurbo is available, interactions found should be confirmed via another method. 
One way to confirm these interactions could be to use fluorescence resonance energy transfer 
(FRET). This term describes a distance dependent process by which energy is transferred from 
an excited fluorophore, known as the donor, to another fluorophore, known as the acceptor 
(Förster., 1965). FRET is an accurate measure of molecular proximity, and hence interaction, 
when proteins tagged with the donor and acceptor fluorophores are within 10nm of each other in 
live cells (Figure 4.2; Förster., 1965). This radius of 10 nm, measurable by FRET, is identical to 
that labelled by TurboID and miniTurbo, as described by Branon et al.,2018. Biotinylated proteins 
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identified by mass spectrometry can then be tagged with fluorescent FRET pairs, such as EGFP 
and mCherry and energy transfer between these established in live cells via confocal based FRET 
experiments (Bajar et al.,2016). 
 
Additionally, the fact that FRET experiments are done on live cells means that FRET on proteins 
biotinylated by TurboID and miniTurbo could be used to identify their location. In turn, this could 
shed light on the localisation conundrum witnessed in this project where biotinylated proteins were 
seen in the nucleus by fluorescent imaging but in the cytoplasm when nuclear extraction was 
conducted. 
 
 
 
 
Figure 4.2 The principle of fluorescent energy transfer (FRET). When proteins tagged with 
an appropriate donor fluorophore, such as GFP, are interacting with (with 10nm protein) tagged 
with an acceptor fluorophore, FRET occurs. 
 
4.8.2 Summary of limitations and contingencies 
In this chapter I have discussed various limitations of this study as well as future directions to 
address these. Below, I summarise the main limitations and contingencies for this study (Table 
4). 
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Table 4- Main limitations and contingencies for this study 
 
Limitation Possible cause Contingency 
 Endotoxins may Conduct DNA extraction 
 have affected the using an endotoxin removal 
 formation of DNA- kit 
 TransIT complexes:  
Limited or reduced 
transfection 
efficiency 
 Attempt transfection 
optimisation using 2 µl/µg 
DNA to 6 µl/µg DNA 
  
  Cell confluency may 
 have been too high Attempt to transfect at 
 at the time of different cell densities 
 transfection  
 
Localisation of 
  
Conduct live cell imaging 
MeCP2 biotinylated Protein expression using FRET as this would 
proteins isn’t may differ in non- allow the visualisation of the 
consistent as seen 
via fluorescence 
fixed cells: transportation of biotinylated 
proteins 
and nuclear   
extraction   
 Protein of interest  Linearise the vector by 
Stable cell line and antibiotic  digestion with BamHI and 
contained non- marker are under  NotI as this would increase 
protein expressing different promoter  the likelihood that both 
cells post antibiotic sequences       insert and vector are        
incorporated together.  
selection   
  Bicistronic vectors can be 
  used to express a 
  recombinant plasmid at 
  higher level. 
Cloning of TBLR1 Restriction sites Use another set of restriction 
was unsuccessful were partially sites that are not 
 complimentary, complimentary 
 leading to inefficient  
 incorporation of the  
 
 restriction sites into 
the insert plasmid Attempt a SLIC method to 
clone the insert into vectors 
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4.9 Implications of this project 
 
Despite decades of research on MeCP2, there is still controversy regarding the role of MeCP2. 
Some controversy arises from 2 of various possible remaining questions: 
-Is MeCP2 solely a transcriptional repressor? 
-Can it truly act also as a transcriptional activator? If so, is this dependent on the tissue type where 
it is being expressed? 
 
Further study of the molecular pathways and hence the protein interactions of this protein is 
required using novel approaches. One such approach is that used in this project. Using PL for 
depicting the protein interactions of MeCP2 may reveal additional targets which may thus reveal 
additional RTT therapeutic avenues to pursue.
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5-Conclusions 
In summary, we have shown that the promiscuous biotin ligases, TurboID and miniTurbo, can be 
effectively tagged to the C-terminus of MeCP2 to biotinylate local proteins in cells. This approach 
addresses some of the deficiencies in other methodologies, such as its ability to identify weak 
interactions and improved specificity. This study provides background work to apply a new 
approach to identifying interacting partners of MeCP2, with potential outcomes on understanding 
and treating RTT. 
 
Both TurboID and miniTurbo require the addition of exogenous biotin in order for biotin labelling 
to begin. The latter is highlighted by the fact that when transfected cells were not exposed to 
biotin, protein presence in the cells did not appear to be different to that of untransfected cells. 
Additionally, both TurboID and miniTurbo are able to biotinylate proteins in as little as 10 minutes. 
This is similar to that found when using the ligases in their unconjugated form and hence it is 
possible to conclude that conjugating the ligase did not to hinder its functionality. 
 
 
Transfection efficiency was too low in this project to enable sufficient biotinylation for pull down 
experiments using streptavidin beads and mass spectrometry analysis. To address this, a stable 
cell line of MeCP2-TurboID and MeCP2-miniTurbo was attempted. Selection using G418 
appeared to be successful as untransfected cells were no longer detected after 7 days, however, 
fluorescent imaging showed the presence on non-protein expressing cells after selection. 
Linearising the vector or employing different cloning methods may be used to address this. 
 
 
I was unable to successfully clone TBLR1 into MeCP2-EGFP and MeCP2-TurboID. Without time 
constraints, the next step would have been to linearise the construct via digestion with BamHI 
and XhoI, as this has been shown to aid successful incorporation of genes of interest into 
mammalian cells or indeed design primers with a different combination of restriction sites. 
Additionally, bicistronic vectors could be employed for the cloning of TBLR1 into the vectors of 
interest. 
 
 
Overall, the successful use of proximity labelling for the biotinylation of proximal proteins 
provides an interesting avenue for the pursuit of knowledge regarding protein interactions. In 
the future, these new constructs may be used for increasing knowledge on RTT by shedding 
light on specific protein interactions, which could, in turn, have significant clinical applications. 
Additionally, the use of biotinylating ligases may be used in constricts with other proteins and 
hence PL is likely to have general applications in the field of protein interactions. 
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